



Viusid, a Nutritional Supplement, Increases Survival and Reduces Disease Progression in HCV-Related Decompensated Cirrhosis. A Randomized and Controlled Trial.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000140
Article Type:	Research
Date Submitted by the Author:	13-Apr-2011
Complete List of Authors:	Vilar Gomez, Eduardo; National Institute of Gastroenterology, Researches Sanchez Rodriguez, Yoan; National Institute of Gastroenterology, Hepatology Torres Gonzalez, Ana; National Institute of Gastroenterology, Hepatology Calzadilla Bertot, Luis; National Institute of Gastroenterology, Hepatology Arus Soler, Enrique; National Institute of Gastroenterology, General director Martinez Perez, Yadina; National Institute of Gastroenterology, Gastroenterology Yasells Garcia, Ali; National Institute of Gastroenterology, Gastroenterology Abreu Vazquez, Maria; National Institute of Gastroenterology, Biostatistics
Primary Subject Heading:	Gastroenterology and hepatology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Gastrointestinal tumours < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 Viusid, a Nutritional Supplement, Increases Survival and Reduces Disease Progression in
5
6 HCV-Related Decompensated Cirrhosis. A Randomized and Controlled Trial.
7
8

9 **Author names:**

10
11 Eduardo Vilar Gomez

12
13 Email: vilar@infomed.sld.cu

14
15
16 Director of Researches. National Institute of Gastroenterology, Havana, Cuba.
17

18
19 Yoan Sanchez Rodriguez

20
21 Email: yoan.sanchez@infomed.sld.cu

22
23 Head of the Department of Hepatology. National Institute of Gastroenterology, Havana,
24
25 Cuba.
26

27
28 Ana Torres Gonzalez

29
30 Email: anylut@infomed.sld.cu

31
32 Department of Hepatology. National Institute of Gastroenterology, Havana, Cuba.
33

34
35 Luis Calzadilla Bertot

36
37 Email: lcbertot@infomed.sld.cu

38
39 Department of Hepatology. National Institute of Gastroenterology, Havana, Cuba.
40

41
42 Enrique Arus Soler

43
44 Email: anayda@infomed.sld.cu

45
46 General Director. National Institute of Gastroenterology, Havana, Cuba.
47

48
49 Yadina Martinez Perez

50
51 Email: yadinamartinez@infomed.sld.cu

52
53 Department of Gastroenterology. National Institute of Gastroenterology, Havana, Cuba.
54

55
56 Ali Yasells Garcia

57
58 Email: yasellsg@gmail.com
59
60

1
2
3
4 Department of Gastroenterology. National Institute of Gastroenterology

5
6 Havana, Cuba

7
8 Maria del Rosario Abreu Vazquez

9
10 Email: charo@infomed.sld.cu

11
12 Department of Biostatistics. National Institute of Gastroenterology, Havana, Cuba

13
14
15 **Corresponding author:**

16
17 EDUARDO VILAR GOMEZ.

18
19 National Institute of Gastroenterology, Havana, Cuba.

20
21 Mailing address: 25th Avenue, 503, Vedado, Havana, Cuba

22
23 E-mail address: vilar@infomed.sld.cu

24
25 Phone number: 53 7 8325067

26
27 Fax number: 53 7 8333253

28
29
30
31
32 **Abbreviations:** HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate
33 aminotransferase; HR, hazard ratio; CI, confidence interval; OS, overall survival; HCC,
34 hepatocellular carcinoma; MELD, model end-stage liver disease; CHC, chronic hepatitis C;
35 OLT, orthotopic liver transplantation; SOC, standard of care; PEG-IFN, peginterferon; RBV,
36 ribavirin; SVR, sustained virological response; IL, interleukin; TNF, tumor necrosis factor;
37 IFN- γ , interferon-gamma; HIV, human immunodeficiency virus; PCR, polymerase chain
38 reaction; SD, standard deviation; ITT, intention-to-treat analysis; SBP, spontaneous bacterial
39 peritonitis; MDA, malondialdehyde; HALT-C, the hepatitis C antiviral long-term treatment
40 against cirrhosis; CO-PILOT, colchicine versus pegintron long-term therapy; EPIC, evaluation
41 of pegintron in control of hepatitis C cirrhosis.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Viusid is a nutritional supplement with recognized antioxidant and immunomodulatory properties which could have beneficial effects on cirrhosis-related clinical outcomes such as survival, disease progression and development of hepatocellular carcinoma. Our study evaluated the efficacy and safety of viusid in patients with HCV-related decompensated cirrhosis. **Design:** A randomized double-blind and placebo-controlled study was conducted in a tertiary care academic center (National Institute of Gastroenterology, Havana, Cuba). We randomly assigned 100 patients with HCV-related decompensated cirrhosis to receive viusid (3 oral sachets daily, n=50) or placebo (n=50) during 96 weeks. Primary and secondary end points were comparisons of overall survival (OS), time to disease progression and time to hepatocellular carcinoma (HCC) diagnosis between groups in the intention-to-treat population. **Results:** Viusid led to a significant improvement in overall survival (90%) versus placebo (74%) (hazard ratio [HR] 0.27, 95% CI: 0.08-0.92; $P=0.036$). A similar improvement in disease progression was seen in viusid-treated patients (28%), compared to placebo-treated patients (48%) (HR 0.47, 95% CI: 0.22-0.89; $P=0.044$). The cumulative incidence of HCC was significantly reduced in patients treated with viusid (2%) as compared to placebo (12%) (HR 0.15, 95% CI: 0.019-0.90; $P=0.046$). Viusid was well tolerated. **Conclusions:** Our results indicate that treatment with viusid leads to a notable improvement in overall clinical outcomes such as survival, disease progression and development of HCC in patients with HCV-related decompensated cirrhosis. The trial had been registered at ClinicalTrials.gov (NCT00502086).

Key words: chronic hepatitis C, cirrhosis of the liver, survival.

Article summary

- HCV-related decompensated cirrhotic patients have a poor therapeutic response and reduced tolerance to the current standard of care (SOC) therapy.
- Therapeutic goals in these patients should be directed towards reducing liver-related morbidity and mortality, and the need for liver transplantation.
- Viusid is a nutritional supplement with recognized antioxidant and immunomodulatory properties that could modulate the histological pattern of CHC, especially inflammation and fibrosis in an attempt to halt disease progression and consequently improve liver function and liver-related morbidity and mortality, and prevent development of HCC.

Key messages

- The administration of viusid to HCV-related decompensated cirrhotic patients induced a significant improvement of overall survival, a significant reduction in the disease progression and development of hepatocellular carcinoma.
- The benefit of Viusid was also seen in the secondary end point of worsening of the prognostic scores such as MELD and CP scores.
- Viusid was well tolerated and only minor transient adverse events such as nausea and diarrhea were reported.

Strengths and limitations of this study

- The main strength of this study was to demonstrate that Viusid improves overall clinical outcomes (survival, HCC, and disease progression) in cirrhotic patients who have failed to achieve SVR with SOC, and these benefits appear to be not associated to viral suppression rates.
- The study was designed with a small sample size.

- 1
2
3
4 • Further multicentre and large-scale studies are needed to corroborate the impact of
5
6 Viusid on the clinical outcomes in patients with HCV-related decompensated cirrhosis.
7
8

9 **Funding statement:** This work was supported in part by a grant from Catalysis
10 Laboratories, Spain. They provided the Viusid and placebo sachets. The supporting
11 sources had no role in the study design, collection of data, interpretation of data, writing of
12 the manuscript, or submission for publication.
13
14
15

16
17
18 **Competing interest statement:** Nothing to declare
19

20
21 **Specific author contributions:**
22

23 The authors were collectively responsible for the study design, data collection,
24 statistical analysis, and interpretation of data; the writing of the manuscript; and the
25 decision to submit the manuscript for publication.
26
27
28

29
30 Eduardo Vilar Gomez was involved in the study concept and design; acquisition of data;
31 analysis and interpretation of data; drafting of the manuscript; critical revision of the
32 manuscript for important intellectual content; statistical analysis; and obtained funding. He
33 has approved the final draft submitted.
34
35
36
37

38
39
40 Yoan Sanchez Rodriguez was involved in the study concept and design; acquisition of
41 data; analysis and interpretation of data; critical revision of the manuscript for important
42 intellectual content; and drafting of the manuscript. He has approved the final draft
43 submitted.
44
45
46
47

48
49
50 Ana Torres Gonzalez was involved in the study concept and design; acquisition of data;
51 analysis and interpretation of data; and drafting of the manuscript. She has approved the
52 final draft submitted.
53
54
55
56
57
58
59
60

1
2
3
4 Luis Calzadilla Bertot was involved in the study concept and design; acquisition of data;
5
6 analysis and interpretation of data; drafting of the manuscript; and critical revision of the
7
8 manuscript for important intellectual content. He has approved the final draft submitted.
9

10
11
12 Enrique Arus Soler was involved in the study concept and design; critical revision of the
13
14 manuscript for important intellectual content; and drafting of the manuscript. He has
15
16 approved the final draft submitted.
17

18
19
20 Yadina Martinez Perez was involved in the study concept and design; acquisition of data;
21
22 analysis and interpretation of data; and drafting of the manuscript. She has approved the
23
24 final draft submitted.
25

26
27
28 Ali Yasells Garcia was involved in the study concept and design; acquisition of data;
29
30 analysis and interpretation of data; drafting of the manuscript; and critical revision of the
31
32 manuscript for important intellectual content. He has approved the final draft submitted.
33

34
35
36 Maria del Rosario Abreu Vazquez was involved in the study concept and design;
37
38 acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical
39
40 revision of the manuscript for important intellectual content; and statistical analysis. She
41
42 has approved the final draft submitted.
43

44 45 **Introduction**

46
47
48 Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease and
49
50 hepatocellular carcinoma (HCC) worldwide ¹, and the most common indication for
51
52 orthotopic liver transplantation (OLT) in the western world ². Once HCV cirrhosis has
53
54 developed, the risk of clinical decompensation is about 5% per year ³⁻⁵, and the risk of
55
56 mortality is considerably high with a survival rate of 50% at 5 years ⁶⁻⁷. Cumulative data of
57
58 patients with compensated cirrhosis indicate that the 5-year risk of decompensation is
59
60

1
2
3
4 estimated to be 15-28%, and the annual risk of developing HCC is 1.4-6.7%^{3-4 8}. Liver-
5
6 related mortality increases considerably as soon as decompensation is established, and
7
8 then liver transplantation is the only successful therapeutic option. However, the limited
9
10 number of liver donors as well as age-related impairment of cardiovascular, renal, and
11
12 pulmonary functions makes this option unavailable to the greater part of patients.
13
14

15
16 Unfortunately, once the liver is grafted, disease recurrence is universal. The recurrence of
17
18 the infection leads to cirrhosis in approximately 25% of the transplant recipients within 5 –
19
20 10 years after transplantation. The cumulative probability of decompensation 1 year after
21
22 cirrhosis is in the order of 30%, and 1-year survival is 46%⁹.
23
24

25
26 HCV-related cirrhotic patients have a poor therapeutic response and reduced tolerance to
27
28 the current standard of care (SOC) therapy¹⁰⁻¹⁵. Peginterferon (PEG-IFN) plus ribavirin
29
30 (RBV) is the recommended treatment strategy for patients with compensated cirrhosis¹⁶.
31
32

33
34 However, the efficacy of antiviral therapy is in this group significantly lower than in
35
36 noncirrhotic patients, achieving the poorest rates of sustained virological response (SVR,
37
38 5-25%) in patients with genotype 1-4¹⁷. Current evidence indicates that antiviral treatment
39
40 with PEG-IFN alone or in combination with RBV reduces the rate of clinical
41
42 decompensation, improves liver-related survival, and decreases the development of HCC,
43
44 but only in those patients who achieved SVR¹⁸⁻²⁰. However, this benefit should be
45
46 balanced with severe side effects that led to therapy discontinuation and derangement of
47
48 liver function in a high proportion of patients with Child-Pugh class B-C cirrhosis.
49
50

51
52 Thus, an effective treatment is needed immediately in cirrhotic patients who have failed to
53
54 achieve SVR or with advanced disease to avoid further deterioration and death. Therefore,
55
56 therapeutic goals in these patients should be directed towards reducing liver-related
57
58 morbidity and mortality, and the need for liver transplantation.
59
60

1
2
3
4 Several studies have demonstrated an important association between increased levels of
5 products related to oxidative stress and advanced stages of the disease²¹⁻²². Likewise,
6
7
8 cytokine dysregulation is thought to play a crucial role in the persistence of viral infection
9
10
11 and as a key mediator in inflammatory and fibrogenic processes in patients with HCV
12
13
14 infection²³.

15
16 Therefore, the administration of compounds with antioxidant and immunomodulatory
17
18
19 properties could be a plausible strategy to halt the natural course of the disease,
20
21 particularly in cirrhotic patients with non-response to SOC or advanced disease.

22
23 Viusid (Catalysis laboratory, Madrid, Spain) is a nutritional supplement that contains
24
25
26 different molecules (ascorbic acid, zinc, and glycyrrhizic acid) with recognized antioxidant
27
28 and immunomodulatory properties (Table 1)²⁴⁻²⁶.

29
30 Encouraging effects of Viusid on liver histology have been reported in patients with chronic
31
32
33 hepatitis C and nonalcoholic fatty liver disease²⁷⁻²⁸.

34
35 Recent data suggest that Viusid improves oxidative stress through reduction of lipid
36
37
38 peroxidation products and has an immunomodulatory effect on cytokine secretion via
39
40
41 increased production of IFN- γ and IL-10, decreased production of IL-1 α , and stabilized
42
43
44 TNF- α secretion in patients with HCV who have failed previous antiviral treatment²⁹.

45
46 All of these effects could modulate the histological pattern of CHC, especially inflammation
47
48
49 and fibrosis in an attempt to halt disease progression and consequently improve liver
50
51
52 function and liver-related morbidity and mortality, and prevent development of HCC.

53
54 Thus, a randomized double-blind and placebo-controlled study was conducted to evaluate
55
56
57 whether Viusid may have a beneficial effect on survival, time to disease progression and
58
59
60 time to diagnosis of HCC in HCV-related cirrhotic patients with decompensated disease.

Materials and Methods

Participants

We recruited 100 patients with HCV liver-related cirrhosis at a tertiary care academic center (National Institute of Gastroenterology, Havana, Cuba) between May 2005 and June 2007 and who fulfilled the following inclusion criteria: male and female patients of 18 to 70 years of age, clinical or histological diagnosis of cirrhosis, naïve patients or non-responders to previous treatment with PEG-IFN plus RBV with decompensated cirrhosis, defined as a Child-Pugh score ≥ 7 or clinical evidence or history of ascites, encephalopathy, upper gastrointestinal bleeding, and/or impaired hepatic synthetic function, who had contraindicated the antiviral treatment, absence of active alcoholism (alcohol abstinence was monitored at each clinic visit in the course of patient interview), and ability to provide informed consent. Patients were excluded if they had presence of other causes of liver disease, uncontrollable clinical or biochemical complications related to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, serum total bilirubin greater than 85 mmol/L (5 mg/dL), international normalized ratio greater than 2.5), serum creatinine greater than 180 mmol/L (2 mg/dL), positive screening for viral hepatitis A and B and HIV, pregnancy or lactation, concomitant disease with reduced life expectancy, severe psychiatric conditions, drug dependence, and evidence of liver cancer at entry into the study on the basis of ultrasonography and α -fetoprotein levels higher than 200 ng/L.

Ethics

The study was conducted in compliance with the Declaration of Helsinki and approved by the ethics committee and the institutional review board of the National Institute of Gastroenterology. All patients provided written informed consent for participation.

Interventions

After initial evaluation, all patients who met the eligibility criteria were consecutively enrolled in the study. They were randomly assigned to receive: Viusid (3 oral sachets daily, n=50) or placebo (3 oral sachets daily, n=50) for 96 weeks.

Randomization was conducted by blocks of 4 (block randomization). It was performed by a health worker experienced in randomization techniques who was not involved in the evaluation or treatment of the participants. The physicians, study coordinators, and patients did not have access to the randomization scheme.

The researchers, study coordinators, and patients were blinded as to the treatment administered. When the patients were allocated, they brought their entry code to the pharmacy which was provided with the randomized list. The code was revealed to the researchers at the end of the study protocol. Catalysis, Spain provided the Viusid and placebo sachets. There was no difference in appearance, smell, and flavor between Viusid and placebo.

Treatment started 4 weeks after the clinical evidence of decompensation had been treated and controlled with appropriate therapy.

Clinical and laboratory assessment

All patients were closely monitored for clinical, biochemical, and hematological assessment at baseline, weekly for the first eight weeks, and every eight weeks thereafter until the end of the study.

Clinical assessment included physical examination along with compliance to the study medication (verified through sachet count). Biochemical and hematological evaluations included complete blood count, liver tests, glucose, coagulation, and renal function tests.

1
2
3
4 We defined overweight as BMI 25 to 30 kg/m² and defined obesity as BMI > 30 kg/m².

5
6 Patient's data with diagnosis of diabetes mellitus at baseline, elevated fasting glucose
7
8 levels (> 6.1 mmol/L), a positive glucose tolerance test and used antidiabetic medication
9
10 were recorded.
11

12
13 Liver ultrasonography and serum α -fetoprotein determinations were carried out at baseline
14
15 and every 24 weeks during the study to screen for hepatocellular carcinoma.
16

17
18 An upper digestive endoscopy was performed before admission.
19

20
21 The HCV-RNA level was quantified by PCR assay (Amplicor Monitor HCV v.2.0; Roche
22
23 Molecular System; lower limit of detection, 600 IU/ml). HCV genotyping was performed by
24
25 reverse hybridization (Inno-LiPA HCV; Innogenetics, Ghent, Belgium).
26

27 28 **Definition of Outcomes**

29
30 The primary outcome of the study was overall survival (OS) which was measured from the
31
32 date of randomization until the date of death (related to liver disease). Patients with liver-
33
34 unrelated death or lost to follow-up were censored at the time of death or discontinuation,
35
36 and patients undergoing liver transplantation were censored at the transplant date.
37

38
39 Secondary outcomes included the time to disease progression, time to diagnosis of HCC,
40
41 time to worsening of the prognostic scoring systems Child-Pugh and MELD, time to a new
42
43 occurrence or relapse for each one of the main clinical complications secondary to portal
44
45 hypertension, and safety.
46

47
48 The time to disease progression was reflected as the time between random assignment
49
50 and disease progression, defined as the incidence of liver-related death, the development
51
52 of hepatocellular carcinoma, or the first occurrence or relapse (only for those patients with
53
54 a previous history of clinical decompensation) of at least one of the following clinical
55
56
57
58
59
60

1
2
3
4 conditions: ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
5
6
7 syndrome, or upper gastrointestinal bleeding secondary to portal hypertension.

8
9 The time to diagnosis of hepatocellular carcinoma was calculated from the date of
10
11 randomization to the date of occurrence of HCC. Diagnosis of HCC was implemented
12
13 using currently accepted diagnostic criteria for HCC ³⁰⁻³².

14
15
16 The time to worsening of the prognostic scores was defined as the time from
17
18 randomization to worsening of the Child-Pugh score in at least 2 points and the MELD
19
20 score in at least 4 points on the basis of independent clinical evaluation on two
21
22 consecutive study visits. The Child-Pugh and MELD scores are measures of the severity
23
24 of liver disease, with higher numbers indicating greater decompensation.
25
26

27
28 The time to a new occurrence or relapse for each one of the main clinical complications
29
30 secondary to portal hypertension was defined from the date of randomization to the date of
31
32 a new occurrence or relapse (only for those patients with a previous history of clinical
33
34 complications) of the following clinical conditions: ascites, hepatic encephalopathy, upper
35
36 gastrointestinal bleeding, hepatorenal syndrome, and spontaneous bacterial peritonitis.
37
38
39 The evidence for each end point was verified and confirmed by two blinded independent
40
41 hepatologists.
42
43

44
45 Safety was assessed by dynamic reports of adverse events (AEs), clinical laboratory test
46
47 (hematological and biochemical analysis), physical examination, and measurement of vital
48
49 sign. The presence of sepsis and hospitalization were included in the safety reports.
50
51
52 Episodes of sepsis were recorded, and they were diagnosed and treated according to
53
54 recommended guidelines. Sepsis was graded as severe if requiring hospitalization or
55
56 treatment discontinuation.
57
58
59
60

Statistical methods

The baseline characteristics were summarized in percentage for categorical variables and as means \pm SD for continuous variables. The chi-square test was applied to categorical variables. The two-sample *t*-test was used to compare means, and the Mann-Whitney *U*-test if they were not normally distributed. Outcome measurements included all patients who were randomized and received at least one dose of study medication (intention-to-treat analysis). The safety analysis included all treated patients who had at least one safety evaluation after baseline.

Both primary and secondary outcomes were analyzed by the Kaplan-Meier method and differences were compared using Cox proportional hazard models adjusted by sex and age, baseline CP and MELD scores, previous history of clinical decompensation, and current use of diuretics and propranolol.

We defined overall survival time at 96 weeks as a primary end point to compute sample size. The study was designed to have a statistical power of 80% to detect an absolute difference of 25% in the survival rates at 96 weeks (95% in the group with Viusid versus 70% in the control group). Considering a type I error of 0.05 and a type II error of 0.20, 43 patients per arm were needed to reach statistical significance. After considering patient loss as a result of dropout, we set the target number of patients at 50 per arm, or 100 in total.

All confidence intervals, significance tests, and resulting *P* values were two-sided, with an alpha level of 0.05.

Statistical analyses were performed using STATA software, release 11.

1
2
3
4 The study was designed by Catalysis Laboratory in conjunction with the principal
5
6 investigator. The data were collected and analyzed by the investigators. All authors had
7
8 access to the data.
9

10 11 **Results**

12 13 **Patients**

14
15
16 Between May 2005 and June 2007, 124 patients were screened. 100 of these patients met
17
18 the eligibility criteria and were randomly assigned to the Viusid (n=50) and the placebo
19
20 arms (n=50). These patients were all included in the intention-to-treat analysis. 24 patients
21
22 were excluded from the study during the screening period because they did not meet the
23
24 inclusion criteria, met one or more of the exclusion criteria, or withdrew their consent. The
25
26 flow of the participants through the trial is presented in Figure 1. None of the patients
27
28 received co-interventions during the trial that could have affected the outcomes. One death
29
30 secondary to myocardial infarction occurred in each group of treatment during the study.
31
32 Four of the 7 patients with HCC were not discontinued and completed the study because
33
34 diagnosis was made only at the end of the treatment.
35
36

37
38
39 Demographic and baseline disease characteristics of the ITT population were generally
40
41 well balanced between treatment arms (Table 2). The patients' mean age was 57.5 years
42
43 and 60% were women. All patients had genotype 1 infection. The mean Child-Pugh and
44
45 MELD scores at baseline were 6.32 and 12.94, respectively.
46
47

48
49 All patients with a previous history of hepatic decompensation were controlled and treated
50
51 with appropriate therapy before trial admission.
52

53
54 At study entry, none of the patients had evidence of hepatocellular carcinoma, ascites,
55
56 hepatic encephalopathy, renal failure, upper gastrointestinal bleeding, or spontaneous
57
58 bacterial peritonitis.
59
60

Efficacy (primary end point)

Overall survival at 96 weeks was significantly higher in the patients assigned to Viusid (90% with a 95% CI, 75 to 95) as compared to the patients assigned to placebo (74% with a 95% CI, 56 to 83) (HR = 0.27; 95% CI, 0.08 to 0.92; $P=0.036$; Figure 2A).

Efficacy (secondary end points)

The Kaplan-Meier estimates of the proportion of patients with disease progression at 96 weeks (Figure 2B) were 28% (95% CI, 19 to 45) in the experimental group and 48% (95% CI, 38 to 66) in the control group. The hazard ratio for the Viusid arm was 0.47 (95% CI, 0.22 to 0.89; $P=0.044$).

The cumulative incidence of hepatocellular carcinoma at 96 weeks was 2% (95% CI, 0.3 to 15) in the Viusid-treated patients and 12% (95% CI, 6 to 33) in the placebo group, with a hazard ratio for the Viusid group of 0.15 (95% CI, 0.019 to 0.90; $P=0.046$) (Figure 2C). All patients with HCC were diagnosed during the second year after randomization. 2 of the 7 patients with HCC were eligible for liver transplantation and 3 had transarterial chemoembolization.

An increase in the Child-Pugh score (Figure 3A) occurred in 7 patients (14%; 95% CI, 8 to 32) allocated to the Viusid group as compared to 19 patients (38%; 95% CI, 30 to 59) allocated to the placebo group. The hazard ratio for the Viusid arm was 0.34 (95% CI, 0.14 to 0.81; $P=0.015$). Likewise, a significant worsening in the MELD score (Figure 3B) was observed in 15 individuals (30%; 95% CI, 21 to 49) assigned to placebo as compared to 6 individuals (12%; 95% CI, 6 to 26) assigned to Viusid, with a hazard ratio for the Viusid group of 0.39 (95% CI, 0.15 to 0.92, $P=0.042$).

The cumulative incidence of ascites at 96 weeks was significantly higher in the patients assigned to placebo (32%; 95% CI, 14 to 39) than in the patients assigned to Viusid (14%,

1
2
3
4 95% CI, 7 to 28). The hazard ratio for the Viusid arm was 0.32 (95% CI, 0.11 to 0.90;
5
6 $P=0.031$), but the differences were not statistically significant for hepatic encephalopathy,
7
8 upper gastrointestinal bleeding, and spontaneous bacterial peritonitis. Type 2 hepatorenal
9
10 syndrome was reported in one patient of each group of treatment. The primary and
11
12 secondary outcome measures are summarized in Table 3.

16 **Safety**

17
18 Cramps (33%), asthenia (32%), sepsis (27%), predominantly bacterial infections, and
19
20 muscle pain (24%) were the most frequent adverse events. The main causes of sepsis
21
22 were urinary infection (11%), SBP (6%), pneumonia (5%), and lymphangitis (3%). None of
23
24 the patients had infections related to leukopenia or neutropenia.

25
26
27
28 A lesser proportion of patients treated with Viusid than treated with placebo had fatigue
29
30 (Viusid, 10%; placebo, 26%; $P=0.04$), cramps (Viusid, 22%; placebo, 44%; $P=0.02$), and
31
32 sepsis (Viusid, 14%; placebo, 40%; $P<0.01$), respectively.

33
34
35 A high percentage of patients (24%) were hospitalized during the study secondary to
36
37 episodes of hepatic decompensation or severe sepsis; however, there was no difference
38
39 between the treatment groups. A summary of adverse events is given in Table 4. There
40
41 were no significant laboratory abnormalities in the two study groups.

42
43
44 Neither was there any incidence of Viusid discontinuation or dose modification secondary
45
46 to adverse events.

49 **Discussion**

50
51
52 HCV-related cirrhotic patients represent an important population with increased morbidity
53
54 and mortality rates. Unfortunately, current antiviral therapy, especially for patients with
55
56 decompensated disease, is generally limited by side effects and early discontinuation is
57
58 common. Therefore, liver transplantation is the most appropriate therapeutic option for
59
60

1
2
3
4 these patients. Recent studies have demonstrated encouraging SVR rates and,
5
6 consequently, clinical outcome improvements (overall survival, HCC, and hepatic
7
8 decompensation) in decompensated cirrhotic patients, but this was only achieved in a
9
10 minority of patients (SVR, 5-25%) infected with genotype 1-4¹⁷. Therefore, there is a
11
12 critical need to explore new therapeutic options for patients with HCV-related end-stage
13
14 liver disease who are never listed for liver transplant and could receive a beneficial impact
15
16 on their clinical outcomes.
17
18

19
20 The study was designed to evaluate the efficacy and safety of Viusid in a particular
21
22 population of elderly cirrhotic patients who had a previous history or current evidence of
23
24 clinical hepatic decompensation and genotype 1 infection, and therefore the poorest
25
26 chance of achieving SVR and elevated probabilities of adverse clinical outcome in their
27
28 next years of follow-up.
29
30

31
32 In the current study, we demonstrated that administration of viusid to HCV-related
33
34 decompensated cirrhotic patients induced a significant improvement of overall survival, as
35
36 compared to placebo. Similarly, a significant reduction in the disease progression, defined
37
38 as the presence liver-related death, the development of hepatocellular carcinoma or a first
39
40 occurrence or relapse of at least one of the main portal hypertension-related clinical
41
42 complications, was observed in patients treated with viusid in comparison to those patients
43
44 treated with placebo. Interestingly, the cumulative incidence of HCC was notably reduced
45
46 in those patients assigned to viusid arm, compared to placebo arm.
47
48

49
50 In the present study, we found increased rates of mortality, disease progression and
51
52 cumulative incidence of HCC in the placebo group than previously reported rates in a
53
54 large, prospective and multicenter trial³³. The most likely explanation for the disparity
55
56 between these rates appears to be related to the difference in the study design. Our study
57
58
59
60

1
2
3
4 was designed to include a large proportion of patients who had a previous history or
5
6 current evidence of clinical hepatic decompensation (poor hepatic reserve), subjects who
7
8 were excluded from the HALT-C Trial³³. A recent controlled study has validated the
9
10 efficacy and safety of IFN-based therapy for HCV-related decompensated cirrhotic patients
11
12¹⁴. One of the main advantages of the study was to include a group of untreated patients
13
14 (controls) with decompensated events who were enrolled to define survival and
15
16 progression disease during 30 months of follow-up. The results obtained in this study show
17
18 that this group of patients have a poor chance to survive (68%) and increased rates of
19
20 hepatic decompensation (88%) and HCC (10%). These results suggest that natural history
21
22 of HCV-related cirrhotic patients is more accelerated in patients with previous history or
23
24 current evidence of clinical hepatic decompensation.
25
26
27
28
29

30 Data from the HALT-C study show an increased annual risk of HCC in patients with a low
31
32 platelet count and the presence of esophageal varices. It could be another reasonable
33
34 theory to explain the increased risk of HCC in our study. In the current study, an elevated
35
36 percentage of patients (~50%) had evidence of esophageal varices and/or
37
38 thrombocytopenia ($<100 \times 10^3/\mu\text{L}$)³⁴.
39
40
41

42 Finally, an increased prevalence of diabetes was reported in our study (42% in placebo
43
44 group and 34% in viusid group), which has been associated with development of HCC and
45
46 accelerated disease progression³⁵.
47
48

49 In the current study, the rate of new occurrence or relapse of overall clinical outcome
50
51 secondary to portal hypertension was statistically reduced in the patients assigned to
52
53 Viusid in comparison to those allocated to placebo. The cumulative incidence of ascites
54
55 was the only remarkable clinical condition reduced in the patients treated with Viusid as
56
57 compared to placebo. In contrast, no differences were observed between the treatment
58
59
60

1
2
3
4 groups for hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
5
6
7 syndrome, and upper gastrointestinal bleeding.

8
9 The benefit of Viusid was also seen in the secondary end point of worsening of the
10
11 prognostic scores. A significant increase in the Child-Pugh and MELD scores was
12
13 observed in the placebo-treated patients compared to the experimental group.

14
15 During the Viusid therapy, the risk of bacterial infections decreased independently from
16
17 neutropenia, which could suggest an improvement in the qualitative neutrophil function,
18
19 but this effect should be additionally studied.
20
21

22
23 Viusid was well tolerated and only minor transient adverse events such as nausea and
24
25 diarrhea were reported.
26
27

28 The mechanisms responsible for the beneficial effects of Viusid on the clinical outcomes
29
30 such as survival, development of HCC, and disease progression have not yet been fully
31
32 studied. However, there are several reasons to understand why its administration might
33
34 improve overall clinical end points.
35
36

37 A recent trial has suggested that Viusid therapy combined with standard of care (SOC) in
38
39 patients with chronic hepatitis C may reduce inflammation and fibrosis, irrespective of
40
41 virological response²⁸. Another recently published study has reported a dual role to
42
43 explain possible mechanisms of action of Viusid on liver histology²⁹. The authors found
44
45 that MDA and 4-hydroxyalkenal levels were significantly reduced in patients treated with
46
47 Viusid, indicating an important effect on lipid peroxidation products. Furthermore, Viusid
48
49 provided immunomodulatory effects on cytokine secretion via increased production of anti-
50
51 inflammatory cytokines (IL-10) and decreased or stabilized production of pro-inflammatory
52
53 cytokines (IL-1 α and TNF- α). Current studies are focusing on the biological effects of
54
55 Viusid on hepatic stellate cell apoptosis as a critical step to clarify the potential mechanism
56
57
58
59
60

1
2
3
4 of Viusid in liver fibrogenesis. On the other hand, it would be important to evaluate whether
5
6 the Viusid effects on the clinical outcomes are directly related to the significant reduction of
7
8 portal pressure in cirrhotic patients. Further studies should be addressed to answer this
9
10 concern.
11

12
13 Recently, the HALT-C study was designed to determine whether low-dose peginterferon
14
15 alpha 2a maintenance therapy over 3.5 years could reduce hepatic decompensation,
16
17 HCC, and mortality in patients with advanced fibrosis or cirrhosis who failed to achieve
18
19 SVR with SOC³³. Unfortunately, no overall reduction in any of these clinical end points
20
21 was achieved. Like the HALT-C study, 2 other studies (COPILOT and EPIC) failed to
22
23 demonstrate overall benefit on clinical outcomes in HCV-related cirrhotic patients³⁶⁻³⁷. A
24
25 recent analysis of the HALT-C trial has demonstrated that benefits on clinical outcomes
26
27 could only be reached in patients with profound viral suppression obtained with full-dose
28
29 peginterferon and ribavirin¹⁹.
30
31
32
33

34
35 The main strength of this study was to demonstrate that Viusid improves overall clinical
36
37 outcomes (survival, HCC, and disease progression) in cirrhotic patients who have failed to
38
39 achieve SVR with SOC, and these benefits appear to be not associated to viral
40
41 suppression rates²⁸.
42
43

44
45 Our study was designed with a small sample size. Therefore, further multicentre and large-
46
47 scale studies are needed to corroborate the impact of Viusid on the clinical outcomes in
48
49 patients with HCV-related decompensated cirrhosis.
50

51
52 In conclusion, the study supports the use of Viusid in patients with HCV-related
53
54 decompensated cirrhosis who have failed to achieve SVR, with full-dose peginterferon and
55
56 ribavirin in an attempt to prevent disease progression and improve overall survival.
57
58
59
60

1
2
3
4 However, additional studies are required to confirm the long-term effect of Viusid in these
5
6 patients.
7

8 9 **References**

- 10
11
12 1 Thomas DL, Seeff LB. Natural history of hepatitis C. *Clin Liver Dis* 2005;**9**:383-98, vi.
13
14 2 Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection.
15
16 *Lancet Infect Dis* 2005;**5**:558-67.
17
18 3 Fattovich G, Pantalena M, Zagni I, *et al.* Effect of hepatitis B and C virus infections on
19
20 the natural history of compensated cirrhosis: a cohort study of 297 patients. *Am J*
21
22 *Gastroenterol* 2002;**97**:2886-95.
23
24 4 Sangiovanni A, Prati GM, Fasani P, *et al.* The natural history of compensated cirrhosis
25
26 due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology* 2006;**43**:1303-
27
28 10.
29
30 5 Benvegna L, Gios M, Boccato S, *et al.* Natural history of compensated viral cirrhosis: a
31
32 prospective study on the incidence and hierarchy of major complications. *Gut* 2004;**53**:744-9.
33
34 6 Fattovich G, Giustina G, Degos F, *et al.* Effectiveness of interferon alfa on incidence of
35
36 hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted
37
38 Action on Viral Hepatitis (EUROHEP). *J Hepatol* 1997;**27**:201-5.
39
40 7 Alazawi W, Cunningham M, Dearden J, *et al.* Systematic review: outcome of
41
42 compensated cirrhosis due to chronic hepatitis C infection. *Aliment Pharmacol Ther*
43
44 2010;**32**:344-55.
45
46 8 Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C
47
48 virus-related cirrhosis and history of parenteral exposure in the United States. *Hepatology*
49
50 1999;**29**:1311-6.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 9 Firpi RJ, Clark V, Soldevila-Pico C, *et al.* The natural history of hepatitis C cirrhosis
5 after liver transplantation. *Liver Transpl* 2009;**15**:1063-71.
6
7
8
9 10 Syed E, Rahbin N, Weiland O, *et al.* Pegylated interferon and ribavirin combination
11 therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver
12 cirrhosis. *Scand J Gastroenterol* 2008;**43**:1378-86.
13
14
15
16 11 Crippin JS, McCashland T, Terrault N, *et al.* A pilot study of the tolerability and efficacy
17 of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. *Liver*
18 *Transpl* 2002;**8**:350-5.
19
20
21
22
23 12 Forns X, Garcia-Retortillo M, Serrano T, *et al.* Antiviral therapy of patients with
24 decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. *J*
25 *Hepatol* 2003;**39**:389-96.
26
27
28
29
30 13 Everson GT, Trotter J, Forman L, *et al.* Treatment of advanced hepatitis C with a low
31 accelerating dosage regimen of antiviral therapy. *Hepatology* 2005;**42**:255-62.
32
33
34
35 14 Iacobellis A, Siciliano M, Perri F, *et al.* Peginterferon alfa-2b and ribavirin in patients
36 with hepatitis C virus and decompensated cirrhosis: a controlled study. *J Hepatol*
37 2007;**46**:206-12.
38
39
40
41
42 15 Tekin F, Gunsar F, Karasu Z, *et al.* Safety, tolerability, and efficacy of pegylated-
43 interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. *Aliment Pharmacol*
44 *Ther* 2008;**27**:1081-5.
45
46
47
48
49 16 Ghany MG, Strader DB, Thomas DL, *et al.* Diagnosis, management, and treatment of
50 hepatitis C: an update. *Hepatology* 2009;**49**:1335-74.
51
52
53
54 17 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic
55 patients with chronic HCV infection. *Expert Opin Pharmacother* 2009;**10**:1929-38.
56
57
58
59
60

- 1
2
3
4 18 Bruno S, Stroffolini T, Colombo M, *et al.* Sustained virological response to interferon-
5 alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
6 Hepatology 2007;**45**:579-87.
7
8
9
10
11 19 Shiffman ML, Morishima C, Dienstag JL, *et al.* Effect of HCV RNA suppression during
12 peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
13 Gastroenterology 2009;**137**:1986-94.
14
15
16
17
18 20 Veldt BJ, Saracco G, Boyer N, *et al.* Long term clinical outcome of chronic hepatitis C
19 patients with sustained virological response to interferon monotherapy. Gut 2004;**53**:1504-8.
20
21
22
23 21 De Maria N, Colantoni A, Fagioli S, *et al.* Association between reactive oxygen
24 species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996;**21**:291-5.
25
26
27
28 22 Boya P, de la Pena A, Beloqui O, *et al.* Antioxidant status and glutathione metabolism
29 in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol
30 1999;**31**:808-14.
31
32
33
34
35 23 Gramenzi A, Andreone P, Loggi E, *et al.* Cytokine profile of peripheral blood
36 mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral
37 Hepat 2005;**12**:525-30.
38
39
40
41
42 24 Duarte TL, Lunec J. Review: When is an antioxidant not an antioxidant? A review of
43 novel actions and reactions of vitamin C. Free Radic Res 2005;**39**:671-86.
44
45
46
47 25 Lee CH, Park SW, Kim YS, *et al.* Protective mechanism of glycyrrhizin on acute liver
48 injury induced by carbon tetrachloride in mice. Biol Pharm Bull 2007;**30**:1898-904.
49
50
51
52 26 Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol
53 Aspects Med 2005;**26**:391-404.
54
55
56
57
58
59
60

- 1
2
3
4 27 Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, *et al.* Clinical trial: a
5 nutritional supplement Viusid, in combination with diet and exercise, in patients with
6 nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2009;**30**:999-1009.
7
8
9
10
11 28 Vilar Gomez E, Gra Oramas B, Soler E, *et al.* Viusid, a nutritional supplement, in
12 combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. *Liver*
13 *Int* 2007;**27**:247-59.
14
15
16
17
18 29 Gomez EV, Perez YM, Sanchez HV, *et al.* Antioxidant and immunomodulatory effects
19 of Viusid in patients with chronic hepatitis C. *World J Gastroenterol* 2010;**16**:2638-47.
20
21
22
23 30 Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology*
24 *2005*;**42**:1208-36.
25
26
27
28 31 Bruix J, Sherman M, Llovet JM, *et al.* Clinical management of hepatocellular
29 carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for
30 the Study of the Liver. *J Hepatol* 2001;**35**:421-30.
31
32
33
34 32 Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular
35 carcinoma. *Gastroenterology* 2005;**128**:1752-64.
36
37
38
39 33 Di Bisceglie AM, Shiffman ML, Everson GT, *et al.* Prolonged therapy of advanced
40 chronic hepatitis C with low-dose peginterferon. *N Engl J Med* 2008;**359**:2429-41.
41
42
43
44 34 Lok AS, Seeff LB, Morgan TR, *et al.* Incidence of hepatocellular carcinoma and
45 associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology*
46 *2009*;**136**:138-48.
47
48
49
50
51 35 Veldt BJ, Chen W, Heathcote EJ, *et al.* Increased risk of hepatocellular carcinoma
52 among patients with hepatitis C cirrhosis and diabetes mellitus. *Hepatology* 2008;**47**:1856-62.
53
54
55
56 36. Afdhal NH, Levine R, Brown R, *et al.* Colchicine versus peginterferon alfa 2b long term
57 therapy: results of the 4 year copilot trial. *J Hepatol* 2008;**48**(Suppl 2):S4.
58
59
60

1
2
3
4 37. Bruix J, Poynard T, Colombo M, *et al.* Pegintron maintenance therapy in cirrhotic
5
6 (Metavir F4) HCV patients, who failed to respond to interferon/ribavirin therapy: final results
7
8 of the EPIC³ cirrhosis maintenance trial. J Hepatol 2009;**50**(Suppl 1):S22.
9
10
11
12
13
14
15
16
17

18 **Table 1.** Ingredients of Viusid
19

20	21	22	23	24	25	26	27	28	29
	Malic acid	0.666 g	Ascorbic acid	0.020 g					
	Glycyrrhizic acid	0.033 g	Folic acid	66 mcg					
	Glucosamine	0.666 g	Cyanocobalamine	0.3 mcg					
	Arginine	0.666 g	Zinc sulfate	0.005 g					
	Glycine	0.333 g	Pyridoxal	0.6 mg					
	Calcium pantothenate	0.002 g							
30									
31									
32									
33									
34									
35									
36									
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									
47									
48									
49									
50									
51									
52									
53									
54									
55									
56									
57									
58									
59									
60									

Table 2. Baseline characteristics.

Variable	Viusid (n=50)	Placebo (n=50)	P value*
Age (y)	58.5±8.9	56.6±8.4	0.29
Sex, n (%)			
Male	22 (44%)	18 (36%)	0.41
Female	28 (56%)	32 (64%)	
BMI (kg/m ²)	25.4±4.6	26.7±4.5	0.16
BMI > 25 (kg/m ²), n (%)	28 (56%)	31 (62%)	0.54
HCV RNA >600,000 IU/ml	42 (84%)	38 (76%)	0.45
Genotype 1, n (%)	50 (100%)	50 (100%)	1.0
Clinical scores			
Child-Pugh Class A	32 (64%)	29 (58%)	0.56
Child-Pugh Class B	15 (30%)	15 (30%)	
Child-Pugh Class C	3 (6%)	6 (12%)	
MELD	12.5±3.7	13.3±4.7	0.46
History of diabetes or fasting glucose ≥ 7 (mmol/L), n (%)	17 (34%)	21 (42%)	0.41
Previous history of clinical decompensation, n (%)†			
Ascites	22 (44%)	14 (32%)	0.10
Upper gastrointestinal bleeding	9 (18%)	5 (10%)	0.25
Spontaneous bacterial peritonitis	2 (4%)	2 (4%)	1.00
Hepatic encephalopathy	4 (8%)	3 (6%)	0.69
Evidence of esophageal varices	23 (46%)	18 (36%)	0.31

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Current propranolol use, n (%)	13 (26%)	10 (20%)	0.65
Average doses	70±17.7	80±37.7	0.37
Current spironolactone use, n (%)	21 (42%)	12 (24%)	0.09
Average doses	84.5±39.1	111±40	0.14
Current furosemide use, n (%)	4 (8%)	5 (10%)	1.00
Average doses	40±10	64±22	0.19
ALT (U/L)	92.2±76.6	82.7±49.5	0.86
AST (U/L)	105±80.2	94.1±56.6	0.72
Fasting plasma glucose (mmol/L)	4.9±1.2	5.1±1.3	0.70
Alkaline phosphatase (mmol/L)	290.4±108	281±78.8	0.96
Creatinine (mmol/L)	1±0.3	1±0.3	0.88
Hemoglobin (g/L)	125.8±13.8	129.5±17.6	0.32
Cholesterol (mmol/L)	3.85±0.9	3.85±1	0.50
Total bilirubin (mmol/L)	24.3±17.6	23.9±17.7	0.98
Albumin (g/L)	38.9±4.3	38.9±4.3	0.52
Partial thromboplastin time (s)	38.4±9.7	39.3±12.3	0.73
Prothrombin time (s)	4.7±2.5	5.5±3.7	0.38
INR	1.49±0.3	1.58±0.4	0.38
White blood cells (x 10 ³ /μL)	6.1±1.9	5.9±1.7	0.70
Platelets (x 10 ³ /μL)	133.7±57.9	130.6±65.7	0.48
Platelets < 100 x 10 ³ /μL	20 (40%)	24 (48%)	0.42
α-fetoprotein (ng/ml)	11±16.9	10±12.7	0.25

* P values are for the comparison between Viusid and placebo.

† Previous history of clinical decompensation within one year before enrollment.

1
2
3
4 Plus-minus values are means \pm standard deviations.

5
6 For all laboratory measures and for continuous demographics: P value Mann-Whitney *U*-test.

7
8 Proportions: percentage, P value chi-square.

9
10
11 MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate
12 aminotransferase.

13
14
15 The Child-Pugh and MELD scores are measures of the severity of liver disease.

16
17 Prothrombin time (s): value is expressed in seconds upper the control.

18
19 Partial thromboplastin time (s): value in seconds.

20
21 To convert mmol/L of bilirubin to mg/dL, multiply by 0.0585.

22
23 To convert mmol/L of creatinine to mg/dL, multiply by 0.01131.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Summary of outcome measures.

Variable	Viusid (N=50) No. of patients (%)	Placebo (N=50) No. of patients (%)	Hazard Ratio* (95% CI)	P value
Primary outcomes – no. (%)				
Survival	45 (90%)	37 (74%)	0.27 (0.08-0.92)	0.036
Secondary outcomes – no. (%)				
Time to disease progression	14 (28%)	24 (48%)	0.47 (0.22-0.89)	0.044
Time to diagnosis of HCC†	1 (2%)	6 (12%)	0.15 (0.019-0.90)	0.046
Worsening of CP score in at least 2 points	7 (14%)	19 (38%)	0.34 (0.14-0.81)	0.015
Worsening of MELD score in at least 4 points	6 (12%)	15 (30%)	0.39 (0.15-0.92)	0.042
Ascites	7 (14%)	16 (32%)	0.32 (0.11-0.90)	0.031
Hepatic encephalopathy	1 (2%)	5 (10%)	0.20 (0.10-1.7)	0.10
Spontaneous bacterial peritonitis	1 (2%)	5 (10%)	0.20 (0.13-1.7)	0.09

1
2
3
4 Upper gastrointestinal bleeding 8 (16%) 10 (20%) 0.78 (0.31-1.99) 0.67
5
6

7 *Hazard ratios were computed using Cox proportional hazard model adjusted for sex and age, baseline CP and MELD scores, previous
8 history of clinical decompensation, and current use of diuretics and propranolol. CI denotes confidence interval for HR.
9

10 †All cases of HCC were diagnosed during the second year of treatment.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 4. Incidence of adverse events*.

Variable	Viusid (n=50)	Placebo (n=50)	P value†
	No (%)	No (%)	
Asthenia	12 (24%)	20 (40%)	0.08
Fatigue or malaise	5 (10%)	13 (26%)	0.04
Muscle pain	8 (16%)	16 (32%)	0.06
Anorexia	5 (10%)	9 (18%)	0.24
Cramps	11 (22%)	22 (44%)	0.02
Discomfort on the RUC‡	7 (14%)	13 (26%)	0.13
Gingival bleeding	5 (10%)	10 (20%)	0.16
Epistaxis	5 (10%)	10 (20%)	0.16
Nausea	5 (10%)	1 (2%)	0.12
Diarrhea	5 (5%)	1 (2%)	0.12
Sepsis	7 (14%)	20 (40%)	<0.01
Hospitalization	9 (18%)	15 (30%)	0.24

* The adverse events listed are those recorded in at least 5% of the patients in either study group.

† P values were calculated on the basis of the two-sided chi-square.

‡ RUC: right upper quadrant.

FIGURE LEGENDS:**Fig. 1. Flow of patients through the study.**

*Four patients with HCC were not discontinued because diagnosis was made at the end of the treatment.

Fig. 2. Kaplan-Meier curves for overall survival (Panel A), time to disease progression (Panel B)*, and time to diagnosis of hepatocellular carcinoma (Panel C), according to intention-to-treat analysis.

*Time to disease progression was defined as the incidence of liver-related death, the development of hepatocellular carcinoma, or the first occurrence or relapse (only for those patients with a previous history of hepatic decompensation) of at least one of the following clinical conditions: ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, or upper gastrointestinal bleeding secondary to portal hypertension. Parentheses show number of events.


Fig. 3. Kaplan-Meier estimates of the time to worsening of the Child-Pugh (Panel A) and MELD (Panel B) scores during the treatment.

Parentheses show number of events.

CONSORT Statement 2001 - Checklist 
 Items to include when reporting a randomized trial

<i>PAPER SECTION And topic</i>	Item	Descriptor	Reported on Page #
<i>TITLE & ABSTRACT</i>	1	<u>How participants were allocated to interventions</u> (e.g., "random allocation", "randomized", or "randomly assigned").	1,3
<i>INTRODUCTION Background</i>	2	<u>Scientific background and explanation of rationale.</u>	6-8
<i>METHODS Participants</i>	3	<u>Eligibility criteria for participants</u> and the <u>settings and locations where the data were collected.</u>	9
Interventions	4	<u>Precise details of the interventions intended for each group and how and when they were actually administered.</u>	10
Objectives	5	<u>Specific objectives and hypotheses.</u>	8
Outcomes	6	<u>Clearly defined primary and secondary outcome measures</u> and, when applicable, any <u>methods used to enhance the quality of measurements</u> (e.g., multiple observations, training of assessors).	11-12
Sample size	7	<u>How sample size was determined</u> and, when applicable, <u>explanation of any interim analyses and stopping rules.</u>	13
Randomization -- Sequence generation	8	<u>Method used to generate the random allocation sequence, including details of any restrictions</u> (e.g., blocking, stratification)	10
Randomization -- Allocation concealment	9	<u>Method used to implement the random allocation sequence</u> (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	10
Randomization -- Implementation	10	<u>Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.</u>	10
Blinding (masking)	11	<u>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment.</u> If done, <u>how the success of blinding was evaluated.</u>	10
Statistical methods	12	<u>Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses</u> , such as subgroup analyses and adjusted analyses.	13
<i>RESULTS Participant flow</i>	13	<u>Flow of participants through each stage</u> (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. <u>Describe protocol deviations from study as planned, together with reasons.</u>	14 Figure 1
Recruitment	14	<u>Dates defining the periods of recruitment and follow-up.</u>	14
Baseline data	15	<u>Baseline demographic and clinical characteristics of each group.</u>	14
Numbers analyzed	16	<u>Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat".</u> State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	14
Outcomes and estimation	17	<u>For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision</u> (e.g., 95% confidence interval).	15-16
Ancillary analyses	18	<u>Address multiplicity by reporting any other analyses performed</u> , including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	15-16
Adverse events	19	<u>All important adverse events or side effects in each intervention group.</u>	16
<i>DISCUSSION Interpretation</i>	20	<u>Interpretation of the results</u> , taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	16-21
Generalizability	21	<u>Generalizability (external validity) of the trial findings.</u>	16-21
Overall evidence	22	<u>General interpretation of the results in the context of current evidence.</u>	16-21

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2A. Overall survival
50x36mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2B. Time to disease progression
50x36mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2C. Time to HCC diagnosis
50x36mm (300 x 300 DPI)

View only




Figure 3A. Time to worsening CP score
50x36mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3B. Time to worsening MELD score
50x36mm (300 x 300 DPI)

View only



Viusid, a Nutritional Supplement, Increases Survival and Reduces Disease Progression in HCV-Related Decompensated Cirrhosis. A Randomized and Controlled Trial.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000140.R1
Article Type:	Research
Date Submitted by the Author:	12-May-2011
Complete List of Authors:	Vilar Gomez, Eduardo; National Institute of Gastroenterology, Researches Sanchez Rodriguez, Yoan; National Institute of Gastroenterology, Hepatology Torres Gonzalez, Ana; National Institute of Gastroenterology, Hepatology Calzadilla Bertot, Luis; National Institute of Gastroenterology, Hepatology Arus Soler, Enrique; National Institute of Gastroenterology, General director Martinez Perez, Yadina; National Institute of Gastroenterology, Gastroenterology Yasells Garcia, Ali; National Institute of Gastroenterology, Gastroenterology Abreu Vazquez, Maria; National Institute of Gastroenterology, Biostatistics
Primary Subject Heading:	Gastroenterology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Gastrointestinal tumours < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 Viusid, a Nutritional Supplement, Increases Survival and Reduces Disease Progression in
5
6 HCV-Related Decompensated Cirrhosis. A Randomized and Controlled Trial.
7
8

9 **Author names:**

10
11 Eduardo Vilar Gomez

12
13 Email: vilar@infomed.sld.cu

14
15
16 Director of Researches. National Institute of Gastroenterology, Havana, Cuba.
17

18
19 Yoan Sanchez Rodriguez

20
21 Email: yoan.sanchez@infomed.sld.cu

22
23 Head of the Department of Hepatology. National Institute of Gastroenterology, Havana,
24
25 Cuba.
26

27
28 Ana Torres Gonzalez

29
30 Email: anylut@infomed.sld.cu

31
32 Department of Hepatology. National Institute of Gastroenterology, Havana, Cuba.
33

34
35 Luis Calzadilla Bertot

36
37 Email: lcbertot@infomed.sld.cu

38
39 Department of Hepatology. National Institute of Gastroenterology, Havana, Cuba.
40

41
42 Enrique Arus Soler

43
44 Email: anayda@infomed.sld.cu

45
46 General Director. National Institute of Gastroenterology, Havana, Cuba.
47

48
49 Yadina Martinez Perez

50
51 Email: yadinamartinez@infomed.sld.cu

52
53 Department of Gastroenterology. National Institute of Gastroenterology, Havana, Cuba.
54

55
56 Ali Yasells Garcia

57
58 Email: yasellsg@gmail.com
59
60

1
2
3
4 Department of Gastroenterology. National Institute of Gastroenterology

5
6 Havana, Cuba

7
8 Maria del Rosario Abreu Vazquez

9
10 Email: charo@infomed.sld.cu

11
12 Department of Biostatistics. National Institute of Gastroenterology, Havana, Cuba

13
14
15 **Corresponding author:**

16
17 EDUARDO VILAR GOMEZ.

18
19 National Institute of Gastroenterology, Havana, Cuba.

20
21 Mailing address: 25th Avenue, 503, Vedado, Havana, Cuba

22
23 E-mail address: vilar@infomed.sld.cu

24
25 Phone number: 53 7 8325067

26
27 Fax number: 53 7 8333253

28
29
30
31
32 **Abbreviations:** HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate
33 aminotransferase; HR, hazard ratio; CI, confidence interval; OS, overall survival; HCC,
34 hepatocellular carcinoma; MELD, model end-stage liver disease; CHC, chronic hepatitis C;
35 OLT, orthotopic liver transplantation; SOC, standard of care; PEG-IFN, peginterferon; RBV,
36 ribavirin; SVR, sustained virological response; IL, interleukin; TNF, tumor necrosis factor;
37 IFN- γ , interferon-gamma; HIV, human immunodeficiency virus; PCR, polymerase chain
38 reaction; SD, standard deviation; ITT, intention-to-treat analysis; SBP, spontaneous bacterial
39 peritonitis; MDA, malondialdehyde; HALT-C, the hepatitis C antiviral long-term treatment
40 against cirrhosis; CO-PILOT, colchicine versus pegintron long-term therapy; EPIC, evaluation
41 of pegintron in control of hepatitis C cirrhosis; [CP, Child-Pugh](#).

Abstract

Objectives: Viusid is a nutritional supplement with recognized antioxidant and immunomodulatory properties which could have beneficial effects on cirrhosis-related clinical outcomes such as survival, disease progression and development of hepatocellular carcinoma. Our study evaluated the efficacy and safety of viusid in patients with HCV-related decompensated cirrhosis. **Design:** A randomized double-blind and placebo-controlled study was conducted in a tertiary care academic center (National Institute of Gastroenterology, Havana, Cuba). We randomly assigned 100 patients with HCV-related decompensated cirrhosis to receive viusid (3 oral sachets daily, n=50) or placebo (n=50) during 96 weeks. Primary and secondary end points were comparisons of overall survival (OS), time to disease progression and time to hepatocellular carcinoma (HCC) diagnosis between groups in the intention-to-treat population. **Results:** Viusid led to a significant improvement in overall survival (90%) versus placebo (74%) (hazard ratio [HR] 0.27, 95% CI: 0.08-0.92; $P=0.036$). A similar improvement in disease progression was seen in viusid-treated patients (28%), compared to placebo-treated patients (48%) (HR 0.47, 95% CI: 0.22-0.89; $P=0.044$). However, the beneficial effects of viusid were wholly observed among patients with Child-Pugh classes B or C, but not among patients with Child-Pugh classes A. The cumulative incidence of HCC was significantly reduced in patients treated with viusid (2%) as compared to placebo (12%) (HR 0.15, 95% CI: 0.019-0.90; $P=0.046$). Viusid was well tolerated. **Conclusions:** Our results indicate that treatment with viusid leads to a notable improvement in overall clinical outcomes such as survival, disease progression and development of HCC in patients with HCV-related decompensated cirrhosis. The trial had been registered at ClinicalTrials.gov (NCT00502086).

Key words: chronic hepatitis C, cirrhosis of the liver, survival.

Article summary

- HCV-related decompensated cirrhotic patients have a poor therapeutic response and reduced tolerance to the current standard of care (SOC) therapy.
- Therapeutic goals in these patients should be directed towards reducing liver-related morbidity and mortality, and the need for liver transplantation.
- Viusid is a nutritional supplement with recognized antioxidant and immunomodulatory properties that could modulate the histological pattern of CHC, especially inflammation and fibrosis in an attempt to halt disease progression and consequently improve liver function and liver-related morbidity and mortality, and prevent development of HCC.

Key messages

- The administration of viusid to HCV-related decompensated cirrhotic patients induced a significant improvement of overall survival, a significant reduction in the disease progression and development of hepatocellular carcinoma.
- The benefit of viusid was also seen in the secondary end point of worsening of the prognostic scores such as MELD and CP scores.
- The viusid effects on survival and disease progression were selective for patients with advanced stage of liver disease (Child-Pugh B or C).
- Viusid was well tolerated and only minor transient adverse events such as nausea and diarrhea were reported.

Strengths and limitations of this study

- The main strength of this study was to demonstrate that viusid improves overall clinical outcomes (survival, HCC, and disease progression) in cirrhotic patients who have failed to achieve SVR with SOC, and these benefits appear to be more prominent in patients with poorer liver function (Child-Pugh B or C).

- The study was designed with a small sample size.
- Further multicentre and large-scale studies are needed to corroborate the impact of viusid on the clinical outcomes in patients with HCV-related decompensated cirrhosis.

Funding statement: This work was supported in part by a grant from Catalysis Laboratories, Spain. They provided the viusid and placebo sachets. The supporting sources had no role in the study design, collection of data, interpretation of data, writing of the manuscript, or submission for publication.

Competing interest statement: Nothing to declare

Specific author contributions:

The authors were collectively responsible for the study design, data collection, statistical analysis, and interpretation of data; the writing of the manuscript; and the decision to submit the manuscript for publication.

Eduardo Vilar Gomez was involved in the study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; and obtained funding. He has approved the final draft submitted.

Yoan Sanchez Rodriguez was involved in the study concept and design; acquisition of data; analysis and interpretation of data; critical revision of the manuscript for important intellectual content; and drafting of the manuscript. He has approved the final draft submitted.

Ana Torres Gonzalez was involved in the study concept and design; acquisition of data; analysis and interpretation of data; and drafting of the manuscript. She has approved the final draft submitted.

1
2
3
4 Luis Calzadilla Bertot was involved in the study concept and design; acquisition of data;
5
6 analysis and interpretation of data; drafting of the manuscript; and critical revision of the
7
8 manuscript for important intellectual content. He has approved the final draft submitted.
9

10
11
12 Enrique Arus Soler was involved in the study concept and design; critical revision of the
13
14 manuscript for important intellectual content; and drafting of the manuscript. He has
15
16 approved the final draft submitted.
17

18
19
20 Yadina Martinez Perez was involved in the study concept and design; acquisition of data;
21
22 analysis and interpretation of data; and drafting of the manuscript. She has approved the
23
24 final draft submitted.
25

26
27
28 Ali Yasells Garcia was involved in the study concept and design; acquisition of data;
29
30 analysis and interpretation of data; drafting of the manuscript; and critical revision of the
31
32 manuscript for important intellectual content. He has approved the final draft submitted.
33

34
35
36 Maria del Rosario Abreu Vazquez was involved in the study concept and design;
37
38 acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical
39
40 revision of the manuscript for important intellectual content; and statistical analysis. She
41
42 has approved the final draft submitted.
43
44

45 **Introduction**

46
47
48 Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease and
49
50 hepatocellular carcinoma (HCC) worldwide ¹, and the most common indication for
51
52 orthotopic liver transplantation (OLT) in the western world ². Once HCV cirrhosis has
53
54 developed, the risk of clinical decompensation is about 5% per year ³⁻⁵, and the risk of
55
56 mortality is considerably high with a survival rate of 50% at 5 years ⁶⁻⁷. Cumulative data of
57
58 patients with compensated cirrhosis indicate that the 5-year risk of decompensation is
59
60

1
2
3
4 estimated to be 15-28%, and the annual risk of developing HCC is 1.4-6.7%^{3-4 8}. Liver-
5
6 related mortality increases considerably as soon as decompensation is established, and
7
8 then liver transplantation is the only successful therapeutic option. Unfortunately, once the
9
10 liver is grafted, disease recurrence is universal. The recurrence of the infection leads to
11
12 cirrhosis in approximately 25% of the transplant recipients within 5 – 10 years after
13
14 transplantation. The cumulative probability of decompensation 1 year after cirrhosis is in
15
16 the order of 30%, and 1-year survival is 46%⁹.

17
18
19
20 HCV-related cirrhotic patients have a poor therapeutic response and reduced tolerance to
21
22 the current standard of care (SOC) therapy¹⁰⁻¹⁵. Peginterferon (PEG-IFN) plus ribavirin
23
24 (RBV) is the recommended treatment strategy for patients with compensated cirrhosis¹⁶.
25
26 However, the efficacy of antiviral therapy is in this group significantly lower than in
27
28 noncirrhotic patients, achieving the poorest rates of sustained virological response (SVR,
29
30 5-25%) in patients with genotype 1-4¹⁷. Current evidence indicates that antiviral treatment
31
32 with PEG-IFN alone or in combination with RBV reduces the rate of clinical
33
34 decompensation, improves liver-related survival, and decreases the development of HCC,
35
36 but only in those patients who achieved SVR¹⁸⁻²⁰. However, this benefit should be
37
38 balanced with severe side effects that led to therapy discontinuation and derangement of
39
40 liver function in a high proportion of patients with Child-Pugh (CP) class B-C cirrhosis.
41
42 Thus, an effective treatment is needed immediately in cirrhotic patients who have failed to
43
44 achieve SVR or with advanced disease to avoid further deterioration and death.
45
46

47
48
49
50 Several studies have demonstrated an important association between increased levels of
51
52 products related to oxidative stress and advanced stages of the disease²¹⁻²². Likewise,
53
54 cytokine dysregulation is thought to play a crucial role in the persistence of viral infection
55
56 and as a key mediator in inflammatory and fibrogenic processes in patients with HCV
57
58
59
60

1
2
3
4 infection²³. Therefore, the administration of compounds with antioxidant and
5
6 immunomodulatory properties could be a plausible strategy to halt the natural course of
7
8 the disease, particularly in cirrhotic patients with advanced disease.
9

10
11 Viusid (Catalyis laboratory, Madrid, Spain) is a nutritional supplement that contains
12
13 different molecules (ascorbic acid, zinc, and glycyrrhizic acid) with recognized antioxidant
14
15 and immunomodulatory properties (Table 1)²⁴⁻²⁶.
16

17
18 Encouraging effects of viusid on liver histology have been reported in patients with chronic
19
20 hepatitis C and nonalcoholic fatty liver disease²⁷⁻²⁸.
21

22
23 Recent data suggest that viusid improves oxidative stress through reduction of lipid
24
25 peroxidation products and has an immunomodulatory effect on cytokine secretion via
26
27 increased production of IFN- γ and IL-10, decreased production of IL-1 α , and stabilized
28
29 TNF- α secretion in patients with HCV who have failed previous antiviral treatment²⁹.
30

31
32 All of these effects could modulate the histological pattern of CHC, especially inflammation
33
34 and fibrosis in an attempt to halt disease progression and consequently improve liver
35
36 function and liver-related morbidity and mortality, and prevent development of HCC.
37

38
39 Thus, a randomized double-blind and placebo-controlled study was conducted to evaluate
40
41 whether viusid may have a beneficial effect on survival, time to disease progression and
42
43 time to diagnosis of HCC in HCV-related cirrhotic patients with decompensated disease.
44
45

46 **Materials and Methods**

47 **Participants**

48
49 We recruited 100 patients with HCV liver-related cirrhosis at a tertiary care academic
50
51 center (National Institute of Gastroenterology, Havana, Cuba) between May 2005 and
52
53 June 2007 and who fulfilled the following inclusion criteria: male and female patients of 18
54
55 to 70 years of age, clinical or histological diagnosis of cirrhosis, naïve patients or non-
56
57
58
59
60

1
2
3
4 responders to previous treatment with PEG-IFN plus RBV with decompensated cirrhosis,
5
6 defined as a Child-Pugh score ≥ 7 or clinical evidence or history of ascites,
7
8 encephalopathy, upper gastrointestinal bleeding, and/or impaired hepatic synthetic
9
10 function, who had contraindicated the antiviral treatment, absence of active alcoholism
11
12 (alcohol abstinence was monitored at each clinic visit in the course of patient interview),
13
14 and ability to provide informed consent. Patients were excluded if they had presence of
15
16 other causes of liver disease, uncontrollable clinical or biochemical complications related
17
18 to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal
19
20 bleeding, serum total bilirubin greater than 85 mmol/L (5 mg/dL), international normalized
21
22 ratio greater than 2.5), serum creatinine greater than 180 mmol/L (2 mg/dL), positive
23
24 screening for viral hepatitis A and B and HIV, pregnancy or lactation, concomitant disease
25
26 with reduced life expectancy, severe psychiatric conditions, drug dependence, and
27
28 evidence of liver cancer at entry into the study on the basis of ultrasonography and α -
29
30 fetoprotein levels higher than 200 ng/L.
31
32
33
34
35

36 37 **Ethics**

38
39 The study was conducted in compliance with the Declaration of Helsinki and approved by the
40
41 ethics committee and the institutional review board of the National Institute of
42
43 Gastroenterology. All patients provided written informed consent for participation.
44
45
46

47 **Interventions**

48
49 After initial evaluation, all patients who met the eligibility criteria were consecutively
50
51 enrolled in the study. They were randomly assigned to receive: viusid (3 oral sachets daily,
52
53 n=50) or placebo (3 oral sachets daily, n=50) for 96 weeks.
54
55

56
57 Randomization was conducted by blocks of 4 (block randomization). It was performed by a
58
59 health worker experienced in randomization techniques who was not involved in the
60

1
2
3
4 evaluation or treatment of the participants. The physicians, study coordinators, and
5
6 patients did not have access to the randomization scheme.
7

8
9 The researchers, study coordinators, and patients were blinded as to the treatment
10
11 administered. When the patients were allocated, they brought their entry code to the
12
13 pharmacy which was provided with the randomized list. The code was revealed to the
14
15 researchers at the end of the study protocol. Catalysis, Spain provided the viusid and
16
17 placebo sachets. There was no difference in appearance, smell, and flavor between viusid
18
19 and placebo.
20
21

22
23 Treatment started 4 weeks after the clinical evidence of decompensation had been treated
24
25 and controlled with appropriate therapy.
26

27 **Clinical and laboratory assessment**

28
29 All patients were closely monitored for clinical, biochemical, and hematological
30
31 assessment at baseline, weekly for the first eight weeks, and every eight weeks thereafter
32
33 until the end of the study.
34
35

36
37 Clinical assessment included physical examination along with compliance to the study
38
39 medication (verified through sachet count). Biochemical and hematological evaluations
40
41 included complete blood count, liver tests, glucose, coagulation, and renal function tests.
42
43

44 We defined overweight as BMI 25 to 30 kg/m² and defined obesity as BMI > 30 kg/m².

45
46 Patient's data with diagnosis of diabetes mellitus at baseline, elevated fasting glucose
47
48 levels (> 6.1 mmol/L), a positive glucose tolerance test and used antidiabetic medication
49
50 were recorded.
51
52

53
54 Liver ultrasonography and serum α -fetoprotein determinations were carried out at baseline
55
56 and every 24 weeks during the study to screen for hepatocellular carcinoma.
57

58
59 An upper digestive endoscopy was performed before admission.
60

1
2
3
4 The HCV-RNA level was quantified by PCR assay (Amplicor Monitor HCV v.2.0; Roche
5 Molecular System; lower limit of detection, 600 IU/ml). HCV genotyping was performed by
6 reverse hybridization (Inno-LiPA HCV; Innogenetics, Ghent, Belgium).
7
8
9

10 11 **Definition of Outcomes**

12
13 The primary outcome of the study was overall survival (OS) which was measured from the
14 date of randomization until the date of death (related to liver disease). Patients with liver-
15 unrelated death or lost to follow-up were censored at the time of death or discontinuation,
16 and patients undergoing liver transplantation were censored at the transplant date.
17
18
19
20

21
22 Secondary outcomes included the time to disease progression, time to diagnosis of HCC,
23 time to worsening of the prognostic scoring systems Child-Pugh and MELD, time to a new
24 occurrence or relapse for each one of the main clinical complications secondary to portal
25 hypertension, and safety.
26
27
28
29
30
31

32
33 The time to disease progression was reflected as the time between random assignment
34 and disease progression, defined as the incidence of liver-related death, the development
35 of hepatocellular carcinoma, or the first occurrence or relapse (only for those patients with
36 a previous history of clinical decompensation) of at least one of the following clinical
37 conditions: ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
38 syndrome, or upper gastrointestinal bleeding secondary to portal hypertension.
39
40
41
42
43
44
45

46
47 The time to diagnosis of hepatocellular carcinoma was calculated from the date of
48 randomization to the date of occurrence of HCC. Diagnosis of HCC was implemented
49 using currently accepted diagnostic criteria for HCC³⁰⁻³².
50
51
52

53
54 The time to worsening of the prognostic scores was defined as the time from
55 randomization to worsening of the Child-Pugh score in at least 2 points and the MELD
56 score in at least 4 points on the basis of independent clinical evaluation on two
57
58
59
60

1
2
3
4 consecutive study visits. The Child-Pugh and MELD scores are measures of the severity
5
6 of liver disease, with higher numbers indicating greater decompensation.
7

8
9 The time to a new occurrence or relapse for each one of the main clinical complications
10
11 secondary to portal hypertension was defined from the date of randomization to the date of
12
13 a new occurrence or relapse (only for those patients with a previous history of clinical
14
15 complications) of the following clinical conditions: ascites, hepatic encephalopathy, upper
16
17 gastrointestinal bleeding, hepatorenal syndrome, and spontaneous bacterial peritonitis.
18

19
20 The evidence for each end point was verified and confirmed by two blinded independent
21
22 hepatologists.
23

24
25 Safety was assessed by dynamic reports of adverse events (AEs), clinical laboratory test
26
27 (hematological and biochemical analysis), physical examination, and measurement of vital
28
29 sign. The presence of sepsis and hospitalization were included in the safety reports.
30

31
32 Episodes of sepsis were recorded, and they were diagnosed and treated according to
33
34 recommended guidelines. Sepsis was graded as severe if requiring hospitalization or
35
36 treatment discontinuation.
37
38

39 40 41 **Statistical methods**

42
43 The baseline characteristics were summarized in percentage for categorical variables and
44
45 as means \pm SD for continuous variables. The chi-square test was applied to categorical
46
47 variables. The two-sample *t*-test was used to compare means, and the Mann-Whitney *U*-
48
49 test if they were not normally distributed. Outcome measurements included all patients
50
51 who were randomized and received at least one dose of study medication (intention-to-
52
53 treat analysis). The safety analysis included all treated patients who had at least one
54
55 safety evaluation after baseline.
56
57
58
59
60

1
2
3
4 Both primary and secondary outcomes were analyzed by the Kaplan-Meier method and
5
6 differences were compared using Cox proportional hazard models adjusted by sex and
7
8 age, baseline CP and MELD scores, previous history of clinical decompensation, and
9
10 current use of diuretics and propranolol.
11
12

13
14 We defined overall survival time at 96 weeks as a primary end point to compute sample
15
16 size. The study was designed to have a statistical power of 80% to detect an absolute
17
18 difference of 25% in the survival rates at 96 weeks (95% in the group with viusid versus
19
20 70% in the control group). Considering a type I error of 0.05 and a type II error of 0.20, 43
21
22 patients per arm were needed to reach statistical significance. After considering patient
23
24 loss as a result of dropout, we set the target number of patients at 50 per arm, or 100 in
25
26 total.
27
28

29
30 All confidence intervals, significance tests, and resulting *P* values were two-sided, with an
31
32 alpha level of 0.05.
33

34
35 Statistical analyses were performed using STATA software, release 11.
36

37
38 The study was designed by Catalysis Laboratory in conjunction with the principal
39
40 investigator. The data were collected and analyzed by the investigators. All authors had
41
42 access to the data.
43

44 **Results**

45 **Patients**

46
47
48
49 Between May 2005 and June 2007, 124 patients were screened. 100 of these patients met
50
51 the eligibility criteria and were randomly assigned to the viusid (n=50) and the placebo
52
53 arms (n=50). These patients were all included in the intention-to-treat analysis. 24 patients
54
55 were excluded from the study during the screening period because they did not meet the
56
57 inclusion criteria, met one or more of the exclusion criteria, or withdrew their consent. The
58
59
60

1
2
3
4 flow of the participants through the trial is presented in Figure 1. None of the patients
5
6 received co-interventions during the trial that could have affected the outcomes. One death
7
8 secondary to myocardial infarction occurred in each group of treatment during the study.
9
10 Four of the 7 patients with HCC were not discontinued and completed the study because
11
12 diagnosis was made only at the end of the treatment.
13
14

15
16 Demographic and baseline disease characteristics of the ITT population were generally
17
18 well balanced between treatment arms (Table 2). The patients' mean age was 57.5 years
19
20 and 60% were women. All patients had genotype 1 infection. The mean CP and MELD
21
22 scores at baseline were 6.32 and 12.94, respectively.
23
24

25
26 All patients with a previous history of hepatic decompensation were controlled and treated
27
28 with appropriate therapy before trial admission.
29

30
31 At study entry, none of the patients had evidence of hepatocellular carcinoma, ascites,
32
33 hepatic encephalopathy, renal failure, upper gastrointestinal bleeding, or spontaneous
34
35 bacterial peritonitis.
36

37 **Efficacy (primary end point)**

38
39 Overall survival at 96 weeks was significantly higher in the patients assigned to viusid
40
41 (90% with a 95% CI, 75 to 95) as compared to the patients assigned to placebo (74% with
42
43 a 95% CI, 56 to 83) (HR = 0.27; 95% CI, 0.08 to 0.92; $P=0.036$; [Table 3](#)). However, the
44
45 beneficial effects of viusid on survival appear to be selective for patients with poor hepatic
46
47 reserve (Child-Pugh B or C) (Figure 2A). Survival in patients with CP classes B or C was
48
49 significantly higher in the viusid group than in the placebo group (80% vs. 48%; HR in the
50
51 viusid group, 0.36; 95% CI, 0.10 to 0.91; $P=0.041$).
52
53
54
55

56 **Efficacy (secondary end points)**

57
58
59
60

1
2
3
4 The Kaplan-Meier estimates of the proportion of patients with disease progression at 96
5 weeks (Table 3) were 28% (95% CI, 19 to 45) in the experimental group and 48% (95%
6 CI, 38 to 66) in the control group. The hazard ratio for the viusid arm was 0.47 (95% CI,
7 0.22 to 0.89; $P=0.044$). Nevertheless, this effect was seen among patients classified as
8 Child-Pugh B or C, but not among patients with CP classes A (Figure 2B). Among patients
9 with CP scores B or C, the disease progression rates were lower in patients treated with
10 viusid (47%) and were progressively higher in patients assigned to placebo arm (80%) (HR
11 in the viusid arm, 0.51; 95% CI, 0.23 to 0.96; $P=0.047$; Figure 2B).

12
13
14
15
16
17
18
19
20
21
22
23 The cumulative incidence of hepatocellular carcinoma at 96 weeks was 2% (95% CI, 0.3 to
24 15) in the viusid-treated patients and 12% (95% CI, 6 to 33) in the placebo group, with a
25 hazard ratio for the viusid group of 0.15 (95% CI, 0.019 to 0.90; $P=0.046$) (Table 3). All
26 patients with HCC were diagnosed during the second year after randomization. 2 of the 7
27 patients with HCC were eligible for liver transplantation and 3 had transarterial
28 chemoembolization.

29
30
31
32
33
34
35
36
37 An increase in the CP score (Figure 3A) occurred in 7 patients (14%; 95% CI, 8 to 32)
38 allocated to the viusid group as compared to 19 patients (38%; 95% CI, 30 to 59) allocated
39 to the placebo group. The hazard ratio for the viusid arm was 0.34 (95% CI, 0.14 to 0.81;
40 $P=0.015$). Likewise, a significant worsening in the MELD score (Figure 3B) was observed
41 in 15 individuals (30%; 95% CI, 21 to 49) assigned to placebo as compared to 6
42 individuals (12%; 95% CI, 6 to 26) assigned to viusid, with a hazard ratio for the Viusid
43 group of 0.39 (95% CI, 0.15 to 0.92, $P=0.042$).

44
45
46
47
48
49
50
51
52
53
54 The cumulative incidence of ascites at 96 weeks was significantly higher in the patients
55 assigned to placebo (32%; 95% CI, 14 to 39) than in the patients assigned to viusid (14%,
56 95% CI, 7 to 28). The hazard ratio for the viusid arm was 0.32 (95% CI, 0.11 to 0.90;
57
58
59
60

1
2
3
4 $P=0.031$), but the differences were not statistically significant for hepatic encephalopathy,
5
6 upper gastrointestinal bleeding, and spontaneous bacterial peritonitis. Type 2 hepatorenal
7
8 syndrome was reported in one patient of each group of treatment. The primary and
9
10 secondary outcome measures are summarized in Table 3.

13 **Safety**

14
15
16 Cramps (33%), asthenia (32%), sepsis (27%), predominantly bacterial infections, and
17
18 muscle pain (24%) were the most frequent adverse events. The main causes of sepsis
19
20 were urinary infection (11%), SBP (6%), pneumonia (5%), and lymphangitis (3%). None of
21
22 the patients had infections related to leukopenia or neutropenia.

23
24
25 A lesser proportion of patients treated with viusid than treated with placebo had fatigue
26
27 (viusid, 10%; placebo, 26%; $P=0.04$), cramps (viusid, 22%; placebo, 44%; $P=0.02$), and
28
29 sepsis (viusid, 14%; placebo, 40%; $P<0.01$), respectively.

30
31
32 A high percentage of patients (24%) were hospitalized during the study secondary to
33
34 episodes of hepatic decompensation or severe sepsis; however, there was no difference
35
36 between the treatment groups. A summary of adverse events is given in Table 4. There
37
38 were no significant laboratory abnormalities in the two study groups.

39
40
41 Neither was there any incidence of viusid discontinuation or dose modification secondary
42
43 to adverse events.

46 **Discussion**

47
48
49 HCV-related cirrhotic patients represent an important population with increased morbidity
50
51 and mortality rates. Unfortunately, current antiviral therapy, especially for patients with
52
53 decompensated disease, is generally limited by side effects and early discontinuation is
54
55 common. Therefore, liver transplantation is the most appropriate therapeutic option for
56
57 these patients. Recent studies have demonstrated encouraging SVR rates and,
58
59
60

1
2
3
4 consequently, clinical outcome improvements (overall survival, HCC, and hepatic
5 decompensation) in decompensated cirrhotic patients, but this was only achieved in a
6
7 minority of patients (SVR, 5-25%) infected with genotype 1-4¹⁷. Therefore, there is a
8
9 critical need to explore new therapeutic options for patients with HCV-related end-stage
10
11 liver disease who are never listed for liver transplant and could receive a beneficial impact
12
13 on their clinical outcomes.
14
15

16
17
18 The study was designed to evaluate the efficacy and safety of vusid in a particular
19
20 population of elderly cirrhotic patients who had a previous history or current evidence of
21
22 clinical hepatic decompensation and genotype 1 infection, and therefore the poorest
23
24 chance of achieving SVR and elevated probabilities of adverse clinical outcome in their
25
26 next years of follow-up.
27
28

29
30 In the current study, we demonstrated that administration of vusid to HCV-related
31
32 decompensated cirrhotic patients induced a significant improvement of overall survival, as
33
34 compared to placebo. Similarly, a significant reduction in the disease progression, defined
35
36 as the presence liver-related death, the development of hepatocellular carcinoma or a first
37
38 occurrence or relapse of at least one of the main portal hypertension-related clinical
39
40 complications, was observed in patients treated with vusid in comparison to those patients
41
42 treated with placebo. However, the effect of vusid on survival and disease progression
43
44 was irrelevant for patients with CP classes A, in contrast to those patients with CP classes
45
46 B or C. Interestingly; the cumulative incidence of HCC was notably reduced in those
47
48 patients assigned to vusid arm, compared to placebo arm. However, a stratified analysis
49
50 according to Child-Pugh classes was not performed, due to a small proportion of patients
51
52 with presence of HCC which could generate a bias in the interpretation of the results.
53
54
55
56
57
58
59
60

1
2
3
4 In the present study, we found increased rates of mortality, disease progression and
5
6 cumulative incidence of HCC in the placebo group than previously reported rates in a
7
8 large, prospective and multicenter trial³³. The most likely explanation for the disparity
9
10 between these rates appears to be related to the difference in the study design. Our study
11
12 was designed to include a large proportion of patients who had a previous history or
13
14 current evidence of clinical hepatic decompensation (poor hepatic reserve), subjects who
15
16 were excluded from the HALT-C Trial³³. A recent controlled study has validated the
17
18 efficacy and safety of IFN-based therapy for HCV-related decompensated cirrhotic patients
19
20¹⁴. One of the main advantages of the study was to include a group of untreated patients
21
22 (controls) with decompensated events who were enrolled to define survival and
23
24 progression disease during 30 months of follow-up. The results obtained in this study show
25
26 that this group of patients have a poor chance to survive (68%) and increased rates of
27
28 hepatic decompensation (88%) and HCC (10%). These results suggest that natural history
29
30 of HCV-related cirrhotic patients is more accelerated in patients with previous history or
31
32 current evidence of clinical hepatic decompensation.
33
34 Data from the HALT-C study show an increased annual risk of HCC in patients with a low
35
36 platelet count and the presence of esophageal varices. It could be another reasonable
37
38 theory to explain the increased risk of HCC in our study. In the current study, an elevated
39
40 percentage of patients (~50%) had evidence of esophageal varices and/or
41
42 thrombocytopenia ($<100 \times 10^3/\mu\text{L}$)³⁴.
43
44
45 Finally, an increased prevalence of diabetes was reported in our study (42% in placebo
46
47 group and 34% in viusid group), which has been associated with development of HCC and
48
49 accelerated disease progression³⁵.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In the current study, the rate of new occurrence or relapse of overall clinical outcome
5 secondary to portal hypertension was statistically reduced in the patients assigned to
6 viusid in comparison to those allocated to placebo. The cumulative incidence of ascites
7 was the only remarkable clinical condition reduced in the patients treated with viusid as
8 compared to placebo. In contrast, no differences were observed between the treatment
9 groups for hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
10 syndrome, and upper gastrointestinal bleeding.
11
12
13
14
15
16
17
18
19

20
21 The benefit of viusid was also seen in the secondary end point of worsening of the
22 prognostic scores. A significant increase in the CP and MELD scores was observed in the
23 placebo-treated patients compared to the experimental group.
24
25
26
27

28 During the viusid therapy, the risk of bacterial infections decreased independently from
29 neutropenia, which could suggest an improvement in the qualitative neutrophil function,
30 but this effect should be additionally studied.
31
32
33

34
35 Viusid was well tolerated and only minor transient adverse events such as nausea and
36 diarrhea were reported.
37
38
39

40 The mechanisms responsible for the beneficial effects of viusid on the clinical outcomes
41 such as survival, development of HCC, and disease progression have not yet been fully
42 studied. However, there are several reasons to understand why its administration might
43 improve overall clinical end points.
44
45
46
47
48

49 A recent trial has suggested that viusid therapy combined with standard of care (SOC) in
50 patients with chronic hepatitis C may reduce inflammation and fibrosis, irrespective of
51 virological response²⁸. Another recently published study has reported a dual role to
52 explain possible mechanisms of action of viusid on liver histology²⁹. The authors found
53 that MDA and 4-hydroxyalkenal levels were significantly reduced in patients treated with
54
55
56
57
58
59
60

1
2
3
4 viusid, indicating an important effect on lipid peroxidation products. Furthermore, viusid
5
6 provided immunomodulatory effects on cytokine secretion via increased production of anti-
7
8 inflammatory cytokines (IL-10) and decreased or stabilized production of pro-inflammatory
9
10 inflammatory cytokines (IL-1 α and TNF- α). Current studies are focusing on the biological effects of
11
12 viusid on hepatic stellate cell apoptosis as a critical step to clarify the potential mechanism
13
14 of viusid in liver fibrogenesis. On the other hand, it would be important to evaluate whether
15
16 the viusid effects on the clinical outcomes are directly related to the significant reduction of
17
18 portal pressure in cirrhotic patients. Further studies should be addressed to answer this
19
20 concern.
21
22
23
24

25
26 Recently, the HALT-C study was designed to determine whether low-dose peginterferon
27
28 alpha 2a maintenance therapy over 3.5 years could reduce hepatic decompensation,
29
30 HCC, and mortality in patients with advanced fibrosis or cirrhosis who failed to achieve
31
32 SVR with SOC³³. Unfortunately, no overall reduction in any of these clinical end points
33
34 was achieved. Like the HALT-C study, 2 other studies (COPILOT and EPIC) failed to
35
36 demonstrate overall benefit on clinical outcomes in HCV-related cirrhotic patients³⁶⁻³⁷. A
37
38 recent analysis of the HALT-C trial has demonstrated that benefits on clinical outcomes
39
40 could only be reached in patients with profound viral suppression obtained with full-dose
41
42 peginterferon and ribavirin¹⁹.
43
44
45
46

47 The main strength of this study was to demonstrate that viusid improves overall clinical
48
49 outcomes (survival, HCC, and disease progression) in cirrhotic patients who have failed to
50
51 achieve SVR with SOC, and these benefits appear to be not associated to viral
52
53 suppression rates²⁸.
54
55
56
57
58
59
60

1
2
3
4 Our study was designed with a small sample size. Therefore, further multicentre and large-
5
6 scale studies are needed to corroborate the impact of vusid on the clinical outcomes in
7
8 patients with HCV-related decompensated cirrhosis.
9

10
11 In conclusion, the study supports the use of vusid in patients with HCV-related
12
13 decompensated cirrhosis who have failed to achieve SVR, with full-dose peginterferon and
14
15 ribavirin in an attempt to prevent disease progression and improve overall survival.
16
17

18 However, additional studies are required to confirm the long-term effect of vusid in
19
20 patients with poorer liver function (Child-Pugh B or C).
21
22

23 **References**

- 24
25
26 1 Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;**9**:383-98, vi.
27
28 2 Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection.
29
30 Lancet Infect Dis 2005;**5**:558-67.
31
32 3 Fattovich G, Pantalena M, Zagni I, *et al.* Effect of hepatitis B and C virus infections on
33
34 the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J
35
36 Gastroenterol 2002;**97**:2886-95.
37
38 4 Sangiovanni A, Prati GM, Fasani P, *et al.* The natural history of compensated cirrhosis
39
40 due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;**43**:1303-
41
42 10.
43
44 5 Benvegna L, Gios M, Boccato S, *et al.* Natural history of compensated viral cirrhosis: a
45
46 prospective study on the incidence and hierarchy of major complications. Gut 2004;**53**:744-9.
47
48 6 Fattovich G, Giustina G, Degos F, *et al.* Effectiveness of interferon alfa on incidence of
49
50 hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted
51
52 Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;**27**:201-5.
53
54
55
56
57
58
59
60

- 1
2
3
4 7 Alazawi W, Cunningham M, Dearden J, *et al.* Systematic review: outcome of
5 compensated cirrhosis due to chronic hepatitis C infection. *Aliment Pharmacol Ther*
6
7 2010;**32**:344-55.
8
9
10
11 8 Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C
12 virus-related cirrhosis and history of parenteral exposure in the United States. *Hepatology*
13
14 1999;**29**:1311-6.
15
16
17
18 9 Firpi RJ, Clark V, Soldevila-Pico C, *et al.* The natural history of hepatitis C cirrhosis
19 after liver transplantation. *Liver Transpl* 2009;**15**:1063-71.
20
21
22
23 10 Syed E, Rahbin N, Weiland O, *et al.* Pegylated interferon and ribavirin combination
24 therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver
25
26
27
28
29
30
31 11 Crippin JS, McCashland T, Terrault N, *et al.* A pilot study of the tolerability and efficacy
32 of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. *Liver*
33
34
35
36
37
38 12 Forns X, Garcia-Retortillo M, Serrano T, *et al.* Antiviral therapy of patients with
39 decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. *J*
40
41
42
43
44
45 13 Everson GT, Trotter J, Forman L, *et al.* Treatment of advanced hepatitis C with a low
46 accelerating dosage regimen of antiviral therapy. *Hepatology* 2005;**42**:255-62.
47
48
49
50 14 Iacobellis A, Siciliano M, Perri F, *et al.* Peginterferon alfa-2b and ribavirin in patients
51 with hepatitis C virus and decompensated cirrhosis: a controlled study. *J Hepatol*
52
53
54
55
56
57
58
59
60

- 1
2
3
4 15 Tekin F, Gunsar F, Karasu Z, *et al.* Safety, tolerability, and efficacy of pegylated-
5
6 interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. *Aliment Pharmacol*
7
8
9 *Ther* 2008;**27**:1081-5.
- 10
11 16 Ghany MG, Strader DB, Thomas DL, *et al.* Diagnosis, management, and treatment of
12
13 hepatitis C: an update. *Hepatology* 2009;**49**:1335-74.
- 14
15
16 17 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic
17
18 patients with chronic HCV infection. *Expert Opin Pharmacother* 2009;**10**:1929-38.
- 19
20 21 Bruno S, Stroffolini T, Colombo M, *et al.* Sustained virological response to interferon-
22
23 alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
24
25
26 *Hepatology* 2007;**45**:579-87.
- 27
28 29 Shiffman ML, Morishima C, Dienstag JL, *et al.* Effect of HCV RNA suppression during
30
31 peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
32
33
34 *Gastroenterology* 2009;**137**:1986-94.
- 35
36 37 Veldt BJ, Saracco G, Boyer N, *et al.* Long term clinical outcome of chronic hepatitis C
38
39 patients with sustained virological response to interferon monotherapy. *Gut* 2004;**53**:1504-8.
- 40
41 42 De Maria N, Colantoni A, Fagioli S, *et al.* Association between reactive oxygen
43
44 species and disease activity in chronic hepatitis C. *Free Radic Biol Med* 1996;**21**:291-5.
- 45
46 47 48 Boya P, de la Pena A, Beloqui O, *et al.* Antioxidant status and glutathione metabolism
49
50 in peripheral blood mononuclear cells from patients with chronic hepatitis C. *J Hepatol*
51
52
53 1999;**31**:808-14.
- 54
55 56 57 58 59 60 23 Gramenzi A, Andreone P, Loggi E, *et al.* Cytokine profile of peripheral blood
mononuclear cells from patients with different outcomes of hepatitis C virus infection. *J Viral*
Hepat 2005;**12**:525-30.

- 1
2
3
4 24 Duarte TL, Lunec J. Review: When is an antioxidant not an antioxidant? A review of
5 novel actions and reactions of vitamin C. *Free Radic Res* 2005;**39**:671-86.
6
7
8
9 25 Lee CH, Park SW, Kim YS, *et al.* Protective mechanism of glycyrrhizin on acute liver
10 injury induced by carbon tetrachloride in mice. *Biol Pharm Bull* 2007;**30**:1898-904.
11
12
13
14 26 Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. *Mol*
15 *Aspects Med* 2005;**26**:391-404.
16
17
18
19 27 Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, *et al.* Clinical trial: a
20 nutritional supplement Viusid, in combination with diet and exercise, in patients with
21 nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2009;**30**:999-1009.
22
23
24
25 28 Vilar Gomez E, Gra Oramas B, Soler E, *et al.* Viusid, a nutritional supplement, in
26 combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. *Liver*
27 *Int* 2007;**27**:247-59.
28
29
30
31
32 29 Gomez EV, Perez YM, Sanchez HV, *et al.* Antioxidant and immunomodulatory effects
33 of Viusid in patients with chronic hepatitis C. *World J Gastroenterol* 2010;**16**:2638-47.
34
35
36
37 30 Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology*
38 2005;**42**:1208-36.
39
40
41
42 31 Bruix J, Sherman M, Llovet JM, *et al.* Clinical management of hepatocellular
43 carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for
44 the Study of the Liver. *J Hepatol* 2001;**35**:421-30.
45
46
47
48 32 Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular
49 carcinoma. *Gastroenterology* 2005;**128**:1752-64.
50
51
52
53 33 Di Bisceglie AM, Shiffman ML, Everson GT, *et al.* Prolonged therapy of advanced
54 chronic hepatitis C with low-dose peginterferon. *N Engl J Med* 2008;**359**:2429-41.
55
56
57
58
59
60

- 1
2
3
4 34 Lok AS, Seeff LB, Morgan TR, *et al.* Incidence of hepatocellular carcinoma and
5 associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology*
6 2009;**136**:138-48.
7
8
9
10
11 35 Veldt BJ, Chen W, Heathcote EJ, *et al.* Increased risk of hepatocellular carcinoma
12 among patients with hepatitis C cirrhosis and diabetes mellitus. *Hepatology* 2008;**47**:1856-62.
13
14 36. Afdhal NH, Levine R, Brown R, *et al.* Colchicine versus peginterferon alfa 2b long term
15 therapy: results of the 4 year copilot trial. *J Hepatol* 2008;**48**(Suppl 2):S4.
16
17
18
19
20 37. Bruix J, Poynard T, Colombo M, *et al.* Pegintron maintenance therapy in cirrhotic
21 (Metavir F4) HCV patients, who failed to respond to interferon/ribavirin therapy: final results
22 of the EPIC³ cirrhosis maintenance trial. *J Hepatol* 2009;**50**(Suppl 1):S22.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Ingredients of viusid

Malic acid	0.666 g	Ascorbic acid	0.020 g
Glycyrrhizic acid	0.033 g	Folic acid	66 mcg
Glucosamine	0.666 g	Cyanocobalamine	0.3 mcg
Arginine	0.666 g	Zinc sulfata	0.005 g
Glycine	0.333 g	Pyridoxal	0.6 mg
Calcium pantothenate	0.002 g		

Table 2. Baseline characteristics.

Variable	Viusid (n=50)	Placebo (n=50)	P value*
Age (y)	58.5±8.9	56.6±8.4	0.29
Sex, n (%)			
Male	22 (44%)	18 (36%)	0.41
Female	28 (56%)	32 (64%)	
BMI (kg/m ²)	25.4±4.6	26.7±4.5	0.16
BMI > 25 (kg/m ²), n (%)	28 (56%)	31 (62%)	0.54
HCV RNA >600,000 IU/ml	42 (84%)	38 (76%)	0.45
Genotype 1, n (%)	50 (100%)	50 (100%)	1.0
Clinical scores			
Child-Pugh Class A	32 (64%)	29 (58%)	0.56
Child-Pugh Class B	15 (30%)	15 (30%)	
Child-Pugh Class C	3 (6%)	6 (12%)	
MELD	12.5±3.7	13.3±4.7	0.46
History of diabetes or fasting glucose ≥ 7 (mmol/L), n (%)	17 (34%)	21 (42%)	0.41
Previous history of clinical decompensation, n (%)†			
Ascites	22 (44%)	14 (32%)	0.10
Upper gastrointestinal bleeding	9 (18%)	5 (10%)	0.25
Spontaneous bacterial peritonitis	2 (4%)	2 (4%)	1.00
Hepatic encephalopathy	4 (8%)	3 (6%)	0.69
Evidence of esophageal varices	23 (46%)	18 (36%)	0.31

Current propranolol use, n (%)	13 (26%)	10 (20%)	0.65
Average doses	70±17.7	80±37.7	0.37
Current spironolactone use, n (%)	21 (42%)	12 (24%)	0.09
Average doses	84.5±39.1	111±40	0.14
Current furosemide use, n (%)	4 (8%)	5 (10%)	1.00
Average doses	40±10	64±22	0.19
ALT (U/L)	92.2±76.6	82.7±49.5	0.86
AST (U/L)	105±80.2	94.1±56.6	0.72
Fasting plasma glucose (mmol/L)	4.9±1.2	5.1±1.3	0.70
Alkaline phosphatase (mmol/L)	290.4±108	281±78.8	0.96
Creatinine (mmol/L)	1±0.3	1±0.3	0.88
Hemoglobin (g/L)	125.8±13.8	129.5±17.6	0.32
Cholesterol (mmol/L)	3.85±0.9	3.85±1	0.50
Total bilirubin (mmol/L)	24.3±17.6	23.9±17.7	0.98
Albumin (g/L)	38.9±4.3	38.9±4.3	0.52
Partial thromboplastin time (s)	38.4±9.7	39.3±12.3	0.73
Prothrombin time (s)	4.7±2.5	5.5±3.7	0.38
INR	1.49±0.3	1.58±0.4	0.38
White blood cells (x 10 ³ /μL)	6.1±1.9	5.9±1.7	0.70
Platelets (x 10 ³ /μL)	133.7±57.9	130.6±65.7	0.48
Platelets < 100 x 10 ³ /μL	20 (40%)	24 (48%)	0.42
α-fetoprotein (ng/ml)	11±16.9	10±12.7	0.25

* P values are for the comparison between viusid and placebo.

† Previous history of clinical decompensation within one year before enrollment.

1
2
3
4 Plus-minus values are means \pm standard deviations.

5
6 For all laboratory measures and for continuous demographics: P value Mann-Whitney *U*-test.

7
8 Proportions: percentage, P value chi-square.

9
10
11 MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate
12 aminotransferase.

13
14
15 The Child-Pugh and MELD scores are measures of the severity of liver disease.

16
17 Prothrombin time (s): value is expressed in seconds upper the control.

18
19 Partial thromboplastin time (s): value in seconds.

20
21 To convert mmol/L of bilirubin to mg/dL, multiply by 0.0585.

22
23 To convert mmol/L of creatinine to mg/dL, multiply by 0.01131.

Table 3. Summary of outcome measures.

Variable	Viusid (N=50) No. of patients (%)	Placebo (N=50) No. of patients (%)	Hazard Ratio* (95% CI)	P value
Primary outcomes – no. (%)				
Overall survival	45 (90%)	37 (74%)	0.27 (0.08-0.92)	0.036
Secondary outcomes – no. (%)				
Time to disease progression	14 (28%)	24 (48%)	0.47 (0.22-0.89)	0.044
Time to diagnosis of HCC†	1 (2%)	6 (12%)	0.15 (0.019-0.90)	0.046
Worsening of CP score in at least 2 points	7 (14%)	19 (38%)	0.34 (0.14-0.81)	0.015
Worsening of MELD score in at least 4 points	6 (12%)	15 (30%)	0.39 (0.15-0.92)	0.042
Ascites	7 (14%)	16 (32%)	0.32 (0.11-0.90)	0.031
Hepatic encephalopathy	1 (2%)	5 (10%)	0.20 (0.10-1.7)	0.10
Spontaneous bacterial peritonitis	1 (2%)	5 (10%)	0.20 (0.13-1.7)	0.09

1
2
3
4 Upper gastrointestinal bleeding 8 (16%) 10 (20%) 0.78 (0.31-1.99) 0.67
5
6

7 *Hazard ratios were computed using Cox proportional hazard model adjusted for sex and age, baseline CP and MELD scores, previous
8 history of clinical decompensation, and current use of diuretics and propranolol. CI denotes confidence interval for HR.
9

10 †All cases of HCC were diagnosed during the second year of treatment.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 4. Incidence of adverse events*.

Variable	Viusid (n=50)	Placebo (n=50)	P value†
	No (%)	No (%)	
Asthenia	12 (24%)	20 (40%)	0.08
Fatigue or malaise	5 (10%)	13 (26%)	0.04
Muscle pain	8 (16%)	16 (32%)	0.06
Anorexia	5 (10%)	9 (18%)	0.24
Cramps	11 (22%)	22 (44%)	0.02
Discomfort on the RUC‡	7 (14%)	13 (26%)	0.13
Gingival bleeding	5 (10%)	10 (20%)	0.16
Epistaxis	5 (10%)	10 (20%)	0.16
Nausea	5 (10%)	1 (2%)	0.12
Diarrhea	5 (5%)	1 (2%)	0.12
Sepsis	7 (14%)	20 (40%)	<0.01
Hospitalization	9 (18%)	15 (30%)	0.24

* The adverse events listed are those recorded in at least 5% of the patients in either study group.

† P values were calculated on the basis of the two-sided chi-square.

‡ RUC: right upper quadrant.

FIGURE LEGENDS:**Fig. 1. Flow of patients through the study.**

*Four patients with HCC were not discontinued because diagnosis was made at the end of the treatment.

Fig. 2. Kaplan-Meier curves for survival (Panel A) and time to disease progression (Panel B)* according to Child-Pugh classes (A versus B or C).

*Time to disease progression was defined as the incidence of liver-related death, the development of hepatocellular carcinoma, or the first occurrence or relapse (only for those patients with a previous history of hepatic decompensation) of at least one of the following clinical conditions: ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, or upper gastrointestinal bleeding secondary to portal hypertension.

The Child-Pugh score is a measure of the severity of liver disease.

Parentheses show number of events.

CP, Child-Pugh class.

Fig. 3. Kaplan-Meier estimates of the time to worsening of the Child-Pugh (Panel A) and MELD (Panel B) scores during the treatment.


Parentheses show number of events.

The MELD and Child-Pugh score are measures of the severity of liver disease.


CONSORT Statement 2001 - Checklist 
 Items to include when reporting a randomized trial

PAPER SECTION And topic	Item	Descriptor	Reported on Page #
TITLE & ABSTRACT	1	<u>How participants were allocated to interventions</u> (e.g., "random allocation", "randomized", or "randomly assigned").	1,3
INTRODUCTION Background	2	<u>Scientific background and explanation of rationale.</u>	6-8
METHODS Participants	3	<u>Eligibility criteria for participants</u> and the <u>settings and locations where the data were collected.</u>	9
Interventions	4	<u>Precise details of the interventions intended for each group and how and when they were actually administered.</u>	10
Objectives	5	<u>Specific objectives and hypotheses.</u>	8
Outcomes	6	<u>Clearly defined primary and secondary outcome measures</u> and, when applicable, any <u>methods used to enhance the quality of measurements</u> (e.g., multiple observations, training of assessors).	11-12
Sample size	7	<u>How sample size was determined</u> and, when applicable, <u>explanation of any interim analyses and stopping rules.</u>	13
Randomization -- Sequence generation	8	<u>Method used to generate the random allocation sequence, including details of any restrictions</u> (e.g., blocking, stratification)	10
Randomization -- Allocation concealment	9	<u>Method used to implement the random allocation sequence</u> (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	10
Randomization -- Implementation	10	<u>Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.</u>	10
Blinding (masking)	11	<u>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment.</u> If done, <u>how the success of blinding was evaluated.</u>	10
Statistical methods	12	<u>Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses</u> , such as subgroup analyses and adjusted analyses.	13
RESULTS Participant flow	13	<u>Flow of participants through each stage</u> (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. <u>Describe protocol deviations from study as planned, together with reasons.</u>	14 Figure 1
Recruitment	14	<u>Dates defining the periods of recruitment and follow-up.</u>	14
Baseline data	15	<u>Baseline demographic and clinical characteristics of each group.</u>	14
Numbers analyzed	16	<u>Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat".</u> State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	14
Outcomes and estimation	17	<u>For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision</u> (e.g., 95% confidence interval).	15-16
Ancillary analyses	18	<u>Address multiplicity by reporting any other analyses performed</u> , including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	15-16
Adverse events	19	<u>All important adverse events or side effects in each intervention group.</u>	16
DISCUSSION Interpretation	20	<u>Interpretation of the results</u> , taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	16-21
Generalizability	21	<u>Generalizability (external validity) of the trial findings.</u>	16-21
Overall evidence	22	<u>General interpretation of the results in the context of current evidence.</u>	16-21

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Survival according to CP classes
 290x211mm (72 x 72 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Time to disease progression according to CP classes
 290x211mm (72 x 72 DPI)

View only




Figure 3A. Time to worsening CP score
50x36mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3B. Time to worsening MELD score
50x36mm (300 x 300 DPI)

View only



Viusid, a Nutritional Supplement, Increases Survival and Reduces Disease Progression in HCV-Related Decompensated Cirrhosis. A Randomized and Controlled Trial.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000140.R2
Article Type:	Research
Date Submitted by the Author:	03-Aug-2011
Complete List of Authors:	Vilar Gomez, Eduardo; National Institute of Gastroenterology, Researches Sanchez Rodriguez, Yoan; National Institute of Gastroenterology, Hepatology Torres Gonzalez, Ana; National Institute of Gastroenterology, Hepatology Calzadilla Bertot, Luis; National Institute of Gastroenterology, Hepatology Arus Soler, Enrique; National Institute of Gastroenterology, General director Martinez Perez, Yadina; National Institute of Gastroenterology, Gastroenterology Yasells Garcia, Ali; National Institute of Gastroenterology, Gastroenterology Abreu Vazquez, Maria; National Institute of Gastroenterology, Biostatistics
Primary Subject Heading:	Gastroenterology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Gastrointestinal tumours < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 Viusid, a Nutritional Supplement, Increases Survival and Reduces Disease Progression in
5
6 HCV-Related Decompensated Cirrhosis. A Randomized and Controlled Trial.
7
8

9 **Author names:**

10
11 Eduardo Vilar Gomez

12
13 Email: vilar@infomed.sld.cu

14
15
16 Director of Researches. National Institute of Gastroenterology, Havana, Cuba.
17

18
19 Yoan Sanchez Rodriguez

20
21 Email: yoan.sanchez@infomed.sld.cu

22
23 Head of the Department of Hepatology. National Institute of Gastroenterology, Havana,
24
25 Cuba.
26

27
28 Ana Torres Gonzalez

29
30 Email: anlut@infomed.sld.cu

31
32 Department of Hepatology. National Institute of Gastroenterology, Havana, Cuba.
33

34
35 Luis Calzadilla Bertot

36
37 Email: lcbertot@infomed.sld.cu

38
39 Department of Hepatology. National Institute of Gastroenterology, Havana, Cuba.
40

41
42 Enrique Arus Soler

43
44 Email: anayda@infomed.sld.cu

45
46 General Director. National Institute of Gastroenterology, Havana, Cuba.
47

48
49 Yadina Martinez Perez

50
51 Email: yadinamartinez@infomed.sld.cu

52
53 Department of Gastroenterology. National Institute of Gastroenterology, Havana, Cuba.
54

55
56 Ali Yasells Garcia

57
58 Email: yasellsg@gmail.com
59
60

1
2
3
4 Department of Gastroenterology. National Institute of Gastroenterology

5
6 Havana, Cuba

7
8 Maria del Rosario Abreu Vazquez

9
10 Email: charo@infomed.sld.cu

11
12 Department of Biostatistics. National Institute of Gastroenterology, Havana, Cuba

13
14
15 **Corresponding author:**

16
17 EDUARDO VILAR GOMEZ.

18
19 National Institute of Gastroenterology, Havana, Cuba.

20
21 Mailing address: 25th Avenue, 503, Vedado, Havana, Cuba

22
23 E-mail address: vilar@infomed.sld.cu

24
25 Phone number: 53 7 8325067

26
27 Fax number: 53 7 8333253

28
29
30
31
32 **Abbreviations:** HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate
33 aminotransferase; HR, hazard ratio; CI, confidence interval; OS, overall survival; HCC,
34 hepatocellular carcinoma; MELD, model end-stage liver disease; CHC, chronic hepatitis C;
35 OLT, orthotopic liver transplantation; SOC, standard of care; PEG-IFN, peginterferon; RBV,
36 ribavirin; SVR, sustained virological response; IL, interleukin; TNF, tumor necrosis factor;
37 IFN- γ , interferon-gamma; HIV, human immunodeficiency virus; PCR, polymerase chain
38 reaction; SD, standard deviation; ITT, intention-to-treat analysis; SBP, spontaneous bacterial
39 peritonitis; MDA, malondialdehyde; HALT-C, the hepatitis C antiviral long-term treatment
40 against cirrhosis; CO-PILOT, colchicine versus pegintron long-term therapy; EPIC, evaluation
41 of pegintron in control of hepatitis C cirrhosis; CP, Child-Pugh.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: Viusid is a nutritional supplement with recognized antioxidant and immunomodulatory properties which could have beneficial effects on cirrhosis-related clinical outcomes such as survival, disease progression and development of hepatocellular carcinoma. Our study evaluated the efficacy and safety of viusid in patients with HCV-related decompensated cirrhosis. **Design:** A randomized double-blind and placebo-controlled study was conducted in a tertiary care academic center (National Institute of Gastroenterology, Havana, Cuba). We randomly assigned 100 patients with HCV-related decompensated cirrhosis to receive viusid (3 oral sachets daily, n=50) or placebo (n=50) during 96 weeks. The primary outcome of the study was overall survival (OS) at 96 weeks and the secondary outcomes included time to disease progression, time to hepatocellular carcinoma (HCC) diagnosis, time to worsening of the prognostic scoring systems Child-Pugh and MELD and time to a new occurrence or relapse for each one of the main clinical complications secondary to portal hypertension at 96 weeks. **Results:** Viusid led to a significant improvement in overall survival (90%) versus placebo (74%) (hazard ratio [HR] 0.27, 95% CI: 0.08-0.92; $P=0.036$). A similar improvement in disease progression was seen in viusid-treated patients (28%), compared to placebo-treated patients (48%) (HR 0.47, 95% CI: 0.22-0.89; $P=0.044$). However, the beneficial effects of viusid were wholly observed among patients with Child-Pugh classes B or C, but not among patients with Child-Pugh classes A. The cumulative incidence of HCC was significantly reduced in patients treated with viusid (2%) as compared to placebo (12%) (HR 0.15, 95% CI: 0.019-0.90; $P=0.046$). Viusid was well tolerated. **Conclusions:** Our results indicate that treatment with viusid leads to a notable improvement in overall clinical outcomes such as survival, disease progression and

1
2
3
4 development of HCC in patients with HCV-related decompensated cirrhosis. The trial had
5
6 been registered at ClinicalTrials.gov (NCT00502086).
7
8

9 **Key words:** chronic hepatitis C, cirrhosis of the liver, survival.

10
11 **Article summary**

- 12
13
14 • HCV-related decompensated cirrhotic patients have a poor therapeutic response and
15 reduced tolerance to the current standard of care (SOC) therapy.
16
17
18 • Therapeutic goals in these patients should be directed towards reducing liver-related
19 morbidity and mortality, and the need for liver transplantation.
20
21
22
23 • Viusid is a nutritional supplement with recognized antioxidant and immunomodulatory
24 properties that could modulate the histological pattern of CHC, especially inflammation
25 and fibrosis in an attempt to halt disease progression and consequently improve liver
26 function and liver-related morbidity and mortality, and prevent development of HCC.
27
28
29
30
31
32

33 **Key messages**

- 34
35 • The administration of viusid to HCV-related decompensated cirrhotic patients induced
36 a significant improvement of overall survival, a significant reduction in the disease
37 progression and development of hepatocellular carcinoma.
38
39
40
41
42 • The benefit of viusid was also seen in the secondary end point of worsening of the
43 prognostic scores such as MELD and CP scores.
44
45
46
47 • The viusid effects on survival and disease progression were selective for patients with
48 advanced stage of liver disease (Child-Pugh B or C).
49
50
51
52 • Viusid was well tolerated and only minor transient adverse events such as nausea and
53 diarrhea were reported.
54
55
56
57
58
59
60

Strengths and limitations of this study

- The main strength of this study was to demonstrate that viusid improves overall clinical outcomes (survival, HCC, and disease progression) in cirrhotic patients who have failed to achieve SVR with SOC, and these benefits appear to be more prominent in patients with poorer liver function (Child-Pugh B or C).
- The study was designed with a small sample size.
- Further multicentre and large-scale studies are needed to corroborate the impact of viusid on the clinical outcomes in patients with HCV-related decompensated cirrhosis.

Funding statement: This work was supported in part by a grant from Catalysis Laboratories, Spain. They provided the viusid and placebo sachets. The supporting sources had no role in the study design, collection of data, interpretation of data, writing of the manuscript, or submission for publication.

All studies related to viusid have been investigator-initiated researches, and Catalysis had no direct involvement in the design of the study, data collection, or preparation of the manuscript. The National Institute of Gastroenterology had no financial interest with the nutritional supplement viusid.

Competing interest statement: Nothing to declare

Specific author contributions:

The authors were collectively responsible for the study design, data collection, statistical analysis, and interpretation of data; the writing of the manuscript; and the decision to submit the manuscript for publication.

Eduardo Vilar Gomez was involved in the study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the

1
2
3
4 manuscript for important intellectual content; statistical analysis; and obtained funding. He
5
6
7 has approved the final draft submitted.
8
9

10 Yoan Sanchez Rodriguez was involved in the study concept and design; acquisition of
11
12 data; analysis and interpretation of data; critical revision of the manuscript for important
13
14 intellectual content; and drafting of the manuscript. He has approved the final draft
15
16 submitted.
17
18

19
20 Ana Torres Gonzalez was involved in the study concept and design; acquisition of data;
21
22 analysis and interpretation of data; and drafting of the manuscript. She has approved the
23
24 final draft submitted.
25
26

27
28 Luis Calzadilla Bertot was involved in the study concept and design; acquisition of data;
29
30 analysis and interpretation of data; drafting of the manuscript; and critical revision of the
31
32 manuscript for important intellectual content. He has approved the final draft submitted.
33
34

35
36 Enrique Arus Soler was involved in the study concept and design; critical revision of the
37
38 manuscript for important intellectual content; and drafting of the manuscript. He has
39
40 approved the final draft submitted.
41
42

43
44 Yadina Martinez Perez was involved in the study concept and design; acquisition of data;
45
46 analysis and interpretation of data; and drafting of the manuscript. She has approved the
47
48 final draft submitted.
49
50

51
52 Ali Yasells Garcia was involved in the study concept and design; acquisition of data;
53
54 analysis and interpretation of data; drafting of the manuscript; and critical revision of the
55
56 manuscript for important intellectual content. He has approved the final draft submitted.
57
58
59
60

1
2
3
4 Maria del Rosario Abreu Vazquez was involved in the study concept and design;
5
6 acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical
7
8 revision of the manuscript for important intellectual content; and statistical analysis. She
9
10 has approved the final draft submitted.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease and hepatocellular carcinoma (HCC) worldwide ¹, and the most common indication for orthotopic liver transplantation (OLT) in the western world ². Once HCV cirrhosis has developed, the risk of clinical decompensation is about 5% per year ³⁻⁵, and the risk of mortality is considerably high with a survival rate of 50% at 5 years ⁶⁻⁷. Cumulative data of patients with compensated cirrhosis indicate that the 5-year risk of decompensation is estimated to be 15-28%, and the annual risk of developing HCC is 1.4-6.7% ^{3-4 8}. Liver-related mortality increases considerably as soon as decompensation is established, and then liver transplantation is the only successful therapeutic option. Unfortunately, once the liver is grafted, disease recurrence is universal. The recurrence of the infection leads to cirrhosis in approximately 25% of the transplant recipients within 5 – 10 years after transplantation. The cumulative probability of decompensation 1 year after cirrhosis is in the order of 30%, and 1-year survival is 46% ⁹.

HCV-related cirrhotic patients have a poor therapeutic response and reduced tolerance to the current standard of care (SOC) therapy ¹⁰⁻¹⁵. Peginterferon (PEG-IFN) plus ribavirin (RBV) is the recommended treatment strategy for patients with compensated cirrhosis ¹⁶. However, the efficacy of antiviral therapy is in this group significantly lower than in noncirrhotic patients, achieving the poorest rates of sustained virological response (SVR, 5-25%) in patients with genotype 1-4 ¹⁷. Current evidence indicates that antiviral treatment with PEG-IFN alone or in combination with RBV reduces the rate of clinical decompensation, improves liver-related survival, and decreases the development of HCC, but only in those patients who achieved SVR ¹⁸⁻²⁰. However, this benefit should be

1
2
3
4 balanced with severe side effects that led to therapy discontinuation and derangement of
5
6 liver function in a high proportion of patients with Child-Pugh (CP) class B-C cirrhosis.

7
8
9 Thus, an effective treatment is needed immediately in cirrhotic patients who have failed to
10
11 achieve SVR or with advanced disease to avoid further deterioration and death.

12
13
14 Several studies have demonstrated an important association between increased levels of
15
16 products related to oxidative stress and advanced stages of the disease²¹⁻²². Likewise,
17
18 cytokine dysregulation is thought to play a crucial role in the persistence of viral infection
19
20 and as a key mediator in inflammatory and fibrogenic processes in patients with HCV
21
22 infection²³. Therefore, the administration of compounds with antioxidant and
23
24 immunomodulatory properties could be a plausible strategy to halt the natural course of
25
26 the disease, particularly in cirrhotic patients with advanced disease.
27
28

29
30 Viusid (Catalys laboratory, Madrid, Spain) is a nutritional supplement that contains
31
32 different molecules (ascorbic acid, zinc, and glycyrrhizic acid) with recognized antioxidant
33
34 and immunomodulatory properties (Table 1)²⁴⁻²⁶. Glycyrrhizin (0.033 g), the most
35
36 important active ingredient of the supplement, is known to have various immune-
37
38 modulating, antiviral and biological response-modifier activities. It has different anti-
39
40 inflammatory properties (increased production of IL-10 [is a potent anti-inflammatory
41
42 cytokine which inhibits the syntheses of many pro-inflammatory proteins]), anti-apoptotic
43
44 effect, hepatocyte proliferation, and stabilization of hepatic cellular membranes²⁷⁻³⁰.

45
46
47 Encouraging effects of viusid on liver histology have been reported in patients with
48
49 nonalcoholic fatty liver disease and chronic hepatitis C³¹⁻³². The authors reported that the
50
51 addition of viusid to the conventional interferon/ribavirin therapy was associated with
52
53 significant histologic and biochemical improvements, especially in patients without
54
55 sustained virological response. In another study the same authors showed that the
56
57
58
59
60

1
2
3
4 administration of viusid combined to a lifestyle modification based on a hypocaloric diet
5
6 and exercise during 6 months was associated with marked histological improvements on
7
8 steatosis, lobular inflammation, ballooning and NAFLD activity score in patients with
9
10 nonalcoholic fatty liver disease. No significant clinical and laboratory adverse events have
11
12 been reported with the use of viusid in previous trials.
13
14

15
16 Recent data suggest that viusid improves oxidative stress through reduction of lipid
17
18 peroxidation products and has an immunomodulatory effect on cytokine secretion via
19
20 increased production of IFN- γ and IL-10, decreased production of IL-1 α , and stabilized
21
22 TNF- α secretion in patients with HCV who have failed previous antiviral treatment³³.
23
24

25
26 All of these effects could modulate the histological pattern of CHC, especially inflammation
27
28 and fibrosis in an attempt to halt disease progression and consequently improve liver
29
30 function and liver-related morbidity and mortality, and prevent development of HCC.
31

32
33 Thus, a randomized double-blind and placebo-controlled study was conducted to evaluate
34
35 whether viusid may have a beneficial effect on survival, time to disease progression and
36
37 time to diagnosis of HCC in HCV-related cirrhotic patients with decompensated disease.
38
39

40 **Materials and Methods**

41 **Participants**

42
43 We recruited 100 patients with HCV liver-related cirrhosis at a tertiary care academic
44
45 center (National Institute of Gastroenterology, Havana, Cuba) between May 2005 and
46
47 June 2007 and who fulfilled the following inclusion criteria: male and female patients of 18
48
49 to 70 years of age, clinical or histological diagnosis of cirrhosis, naïve patients or non-
50
51 responders to previous treatment with PEG-IFN plus RBV with decompensated cirrhosis,
52
53 defined as a Child-Pugh score ≥ 7 or clinical evidence or history of ascites,
54
55 encephalopathy, upper gastrointestinal bleeding, and/or impaired hepatic synthetic
56
57
58
59
60

1
2
3
4 function, who had contraindicated the antiviral treatment, absence of active alcoholism
5 (alcohol abstinence was monitored at each clinic visit in the course of patient interview),
6
7 and ability to provide informed consent. Patients were excluded if they had presence of
8
9 other causes of liver disease, uncontrollable clinical or biochemical complications related
10
11 to severe liver failure (hepatic encephalopathy, hepatorenal syndrome, gastrointestinal
12
13 bleeding, serum total bilirubin greater than 85 mmol/L (5 mg/dL), international normalized
14
15 ratio greater than 2.5), serum creatinine greater than 180 mmol/L (2 mg/dL), positive
16
17 screening for viral hepatitis A and B and HIV, pregnancy or lactation, concomitant disease
18
19 with reduced life expectancy, severe psychiatric conditions, drug dependence, and
20
21 evidence of liver cancer at entry into the study on the basis of ultrasonography and α -
22
23 fetoprotein levels higher than 200 ng/L.
24
25
26
27
28
29

30 **Ethics**

31
32 The study was conducted in compliance with the Declaration of Helsinki and approved by the
33
34 ethics committee and the institutional review board of the National Institute of
35
36 Gastroenterology. All patients provided written informed consent for participation.
37
38
39

40 **Interventions**

41
42 After initial evaluation, all patients who met the eligibility criteria were consecutively
43
44 enrolled in the study. They were randomly assigned to receive: viusid (3 oral sachets daily,
45
46 n=50) or placebo (3 oral sachets daily, n=50) for 96 weeks.
47
48

49
50 Randomization was conducted by blocks of 4 (block randomization). It was performed by a
51
52 health worker experienced in randomization techniques who was not involved in the
53
54 evaluation or treatment of the participants. The physicians, study coordinators, and
55
56 patients did not have access to the randomization scheme.
57
58
59
60

1
2
3
4 The researchers, study coordinators, and patients were blinded as to the treatment
5 administered. When the patients were allocated, they brought their entry code to the
6 pharmacy which was provided with the randomized list. The code was revealed to the
7 researchers at the end of the study protocol. Catalysis, Spain provided the viusid and
8 placebo sachets. There was no difference in appearance, smell, and flavor between viusid
9 and placebo.
10
11
12
13
14
15
16
17

18 Treatment started 4 weeks after the clinical evidence of decompensation had been treated
19 and controlled with appropriate therapy.
20
21
22

23 **Clinical and laboratory assessment**

24
25 All patients were closely monitored for clinical, biochemical, and hematological
26 assessment at baseline, weekly for the first eight weeks, and every eight weeks thereafter
27 until the end of the study.
28
29
30
31
32

33 Clinical assessment included physical examination along with compliance to the study
34 medication (verified through sachet count). Biochemical and hematological evaluations
35 included complete blood count, liver tests, glucose, coagulation, and renal function tests.
36
37
38

39 We defined overweight as BMI 25 to 30 kg/m² and defined obesity as BMI > 30 kg/m².

40 Patient's data with diagnosis of diabetes mellitus at baseline, elevated fasting glucose
41 levels (> 6.1 mmol/L), a positive glucose tolerance test and used antidiabetic medication
42 were recorded.
43
44
45
46
47
48

49 Liver ultrasonography and serum α -fetoprotein determinations were carried out at baseline
50 and every 24 weeks during the study to screen for hepatocellular carcinoma.
51
52

53 An upper digestive endoscopy was performed before admission.
54
55
56
57
58
59
60

1
2
3
4 The HCV-RNA level was quantified by PCR assay (Amplicor Monitor HCV v.2.0; Roche
5 Molecular System; lower limit of detection, 600 IU/ml). HCV genotyping was performed by
6
7 reverse hybridization (Inno-LiPA HCV; Innogenetics, Ghent, Belgium).
8
9

10 11 **Definition of Outcomes**

12
13 The terminology to define outcomes in this study was slightly modified as compared with
14
15 the original protocol because it is more precise and less subjective to assess time
16
17 dependent clinical complications in cirrhotic patients. Additionally, primary and secondary
18
19 outcomes are in accordance to standardized terminology used in the majority of the trials
20
21 evaluating the impact of treatments on patients with HCV-related cirrhosis.
22
23

24
25 The primary outcome of the study was overall survival (OS) which was measured from the
26
27 date of randomization until the date of death (related to liver disease). Patients with liver-
28
29 unrelated death or lost to follow-up were censored at the time of death or discontinuation,
30
31 and patients undergoing liver transplantation were censored at the transplant date.
32
33

34
35 Secondary outcomes included the time to disease progression, time to diagnosis of HCC,
36
37 time to worsening of the prognostic scoring systems Child-Pugh and MELD, time to a new
38
39 occurrence or relapse for each one of the main clinical complications secondary to portal
40
41 hypertension, and safety.
42
43

44
45 The time to disease progression was reflected as the time between random assignment
46
47 and disease progression, defined as the incidence of liver-related death, the development
48
49 of hepatocellular carcinoma, or the first occurrence or relapse (only for those patients with
50
51 a previous history of clinical decompensation) of at least one of the following clinical
52
53 conditions: ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
54
55 syndrome, or upper gastrointestinal bleeding secondary to portal hypertension.
56
57
58
59
60

1
2
3
4 The time to diagnosis of hepatocellular carcinoma was calculated from the date of
5 randomization to the date of occurrence of HCC. Diagnosis of HCC was implemented
6 using currently accepted diagnostic criteria for HCC³⁴⁻³⁶.
7
8

9
10
11 The time to worsening of the prognostic scores was defined as the time from
12 randomization to worsening of the Child-Pugh score in at least 2 points and the MELD
13 score in at least 4 points on the basis of independent clinical evaluation on two
14 consecutive study visits. The Child-Pugh and MELD scores are measures of the severity
15 of liver disease, with higher numbers indicating greater decompensation.
16
17

18
19 The time to a new occurrence or relapse for each one of the main clinical complications
20 secondary to portal hypertension was defined from the date of randomization to the date of
21 a new occurrence or relapse (only for those patients with a previous history of clinical
22 complications) of the following clinical conditions: ascites, hepatic encephalopathy, upper
23 gastrointestinal bleeding, hepatorenal syndrome, and spontaneous bacterial peritonitis.
24
25

26
27 The evidence for each end point was verified and confirmed by two blinded independent
28 hepatologists.
29
30

31
32 Safety was assessed by dynamic reports of adverse events (AEs), clinical laboratory test
33 (hematological and biochemical analysis), physical examination, and measurement of vital
34 sign. The presence of sepsis and hospitalization were included in the safety reports.
35
36

37
38 Episodes of sepsis were recorded, and they were diagnosed and treated according to
39 recommended guidelines. Sepsis was graded as severe if requiring hospitalization or
40 treatment discontinuation.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical methods

The baseline characteristics were summarized in percentage for categorical variables and as means \pm SD for continuous variables. The chi-square test was applied to categorical variables. The two-sample *t*-test was used to compare means, and the Mann-Whitney *U*-test if they were not normally distributed. Outcome measurements included all patients who were randomized and received at least one dose of study medication (intention-to-treat analysis). The safety analysis included all treated patients who had at least one safety evaluation after baseline.

Both primary and secondary outcomes were analyzed by the Kaplan-Meier method and differences were compared using Cox proportional hazard models adjusted by sex and age, baseline CP and MELD scores, previous history of clinical decompensation, and current use of diuretics and propranolol.

We defined overall survival time at 96 weeks as a primary end point to compute sample size. The study was designed to have a statistical power of 80% to detect an absolute difference of 25% in the survival rates at 96 weeks (95% in the experimental group versus 70% in the control group). Considering a type I error of 0.05 and a type II error of 0.20, 43 patients per arm were needed to reach statistical significance. After considering patient loss as a result of dropout, we set the target number of patients at 50 per arm, or 100 in total.

All confidence intervals, significance tests, and resulting *P* values were two-sided, with an alpha level of 0.05.

Statistical analyses were performed using STATA software, release 11.

1
2
3
4 The study was designed by Catalysis Laboratory in conjunction with the principal
5
6 investigator. The data were collected and analyzed by the investigators. All authors had
7
8 access to the data.
9

10 11 **Results**

12 13 **Patients**

14
15
16 Between May 2005 and June 2007, 124 patients were screened. 100 of these patients met
17
18 the eligibility criteria and were randomly assigned to the viusid (n=50) and the placebo
19
20 arms (n=50). These patients were all included in the intention-to-treat analysis. 24 patients
21
22 were excluded from the study during the screening period because they did not meet the
23
24 inclusion criteria, met one or more of the exclusion criteria, or withdrew their consent. The
25
26 flow of the participants through the trial is presented in Figure 1. None of the patients
27
28 received co-interventions during the trial that could have affected the outcomes. One death
29
30 secondary to myocardial infarction occurred in each group of treatment during the study.
31
32 Four of the 7 patients with HCC were not discontinued and completed the study because
33
34 diagnosis was made only at the end of the treatment.
35
36

37
38
39 Demographic and baseline disease characteristics of the ITT population were generally
40
41 well balanced between treatment arms (Table 2). The patients' mean age was 57.5 years
42
43 and 60% were women. All patients had genotype 1 infection. The mean CP and MELD
44
45 scores at baseline were 6.32 and 12.94, respectively.
46
47

48
49 All patients with a previous history of hepatic decompensation were controlled and treated
50
51 with appropriate therapy before trial admission.
52

53
54 At study entry, none of the patients had evidence of hepatocellular carcinoma, ascites,
55
56 hepatic encephalopathy, renal failure, upper gastrointestinal bleeding, or spontaneous
57
58 bacterial peritonitis.
59
60

Efficacy (primary end point)

Overall survival at 96 weeks was significantly higher in the patients assigned to the nutritional supplement (90% with a 95% CI, 75 to 95) as compared to the patients assigned to placebo (74% with a 95% CI, 56 to 83) (HR = 0.27; 95% CI, 0.08 to 0.92; $P=0.036$; Table 3). However, the beneficial effects of viusid on survival appear to be selective for patients with poor hepatic reserve (Child-Pugh B or C) (Figure 2A). Survival in patients with CP classes B or C was significantly higher in the experimental group than in the placebo group (80% vs. 48%; HR in the viusid group, 0.36; 95% CI, 0.10 to 0.91; $P=0.041$).

Efficacy (secondary end points)

The Kaplan-Meier estimates of the proportion of patients with disease progression at 96 weeks (Table 3) were 28% (95% CI, 19 to 45) in the experimental group and 48% (95% CI, 38 to 66) in the control group. The hazard ratio for the viusid arm was 0.47 (95% CI, 0.22 to 0.89; $P=0.044$). Nevertheless, this effect was seen among patients classified as Child-Pugh B or C, but not among patients with CP classes A (Figure 2B). Among patients with CP scores B or C, the disease progression rates were lower in patients treated with the experimental intervention (47%) and were progressively higher in patients assigned to placebo arm (80%) (HR in the viusid arm, 0.51; 95% CI, 0.23 to 0.96; $P=0.047$; Figure 2B). The cumulative incidence of hepatocellular carcinoma at 96 weeks was 2% (95% CI, 0.3 to 15) in the active product-treated patients and 12% (95% CI, 6 to 33) in the placebo group, with a hazard ratio for the group assigned to active product of 0.15 (95% CI, 0.019 to 0.90; $P=0.046$) (Table 3). All patients with HCC were diagnosed during the second year after randomization. 2 of the 7 patients with HCC were eligible for liver transplantation and 3 had transarterial chemoembolization.

1
2
3
4 An increase in the CP score (Figure 3A) occurred in 7 patients (14%; 95% CI, 8 to 32)
5
6 allocated to the nutritional supplement group as compared to 19 patients (38%; 95% CI, 30
7
8 to 59) allocated to the placebo group. The hazard ratio for the viusid arm was 0.34 (95%
9
10 CI, 0.14 to 0.81; $P=0.015$). Likewise, a significant worsening in the MELD score (Figure
11
12 3B) was observed in 15 individuals (30%; 95% CI, 21 to 49) assigned to placebo as
13
14 compared to 6 individuals (12%; 95% CI, 6 to 26) assigned to nutritional supplement, with
15
16 a hazard ratio for the viusid group of 0.39 (95% CI, 0.15 to 0.92, $P=0.042$).
17
18

19
20 The cumulative incidence of ascites at 96 weeks was significantly higher in the patients
21
22 assigned to placebo (32%; 95% CI, 14 to 39) than in the patients assigned to viusid (14%,
23
24 95% CI, 7 to 28). The hazard ratio for the viusid arm was 0.32 (95% CI, 0.11 to 0.90;
25
26 $P=0.031$), but the differences were not statistically significant for hepatic encephalopathy,
27
28 upper gastrointestinal bleeding, and spontaneous bacterial peritonitis. Type 2 hepatorenal
29
30 syndrome was reported in one patient of each group of treatment. The primary and
31
32 secondary outcome measures are summarized in Table 3.
33
34
35

36 37 **Safety**

38
39 Cramps (33%), asthenia (32%), sepsis (27%), predominantly bacterial infections, and
40
41 muscle pain (24%) were the most frequent adverse events. The main causes of sepsis
42
43 were urinary infection (11%), SBP (6%), pneumonia (5%), and lymphangitis (3%). None of
44
45 the patients had infections related to leukopenia or neutropenia.
46
47
48

49
50 A lesser proportion of patients treated with the nutritional product than treated with placebo
51
52 had fatigue (experimental group, 10%; placebo, 26%; $P=0.04$), cramps (experimental
53
54 group, 22%; placebo, 44%; $P=0.02$), and sepsis (experimental group, 14%; placebo, 40%;
55
56 $P<0.01$), respectively.
57
58
59
60

1
2
3
4 A high percentage of patients (24%) were hospitalized during the study secondary to
5
6 episodes of hepatic decompensation or severe sepsis; however, there was no difference
7
8 between the treatment groups. A summary of adverse events is given in Table 4. There
9
10 were no significant laboratory abnormalities in the two study groups.
11
12

13
14 Neither was there any incidence of viusid discontinuation or dose modification secondary
15
16 to adverse events.
17

18 **Discussion**

19
20 HCV-related cirrhotic patients represent an important population with increased morbidity
21
22 and mortality rates. Unfortunately, current antiviral therapy, especially for patients with
23
24 decompensated disease, is generally limited by side effects and early discontinuation is
25
26 common. Therefore, liver transplantation is the most appropriate therapeutic option for
27
28 these patients. Recent studies have demonstrated encouraging SVR rates and,
29
30 consequently, clinical outcome improvements (overall survival, HCC, and hepatic
31
32 decompensation) in decompensated cirrhotic patients, but this was only achieved in a
33
34 minority of patients (SVR, 5-25%) infected with genotype 1-4¹⁷. Therefore, there is a
35
36 critical need to explore new therapeutic options for patients with HCV-related end-stage
37
38 liver disease who are never listed for liver transplant and could receive a beneficial impact
39
40 on their clinical outcomes.
41
42
43
44
45

46
47 The study was designed to evaluate the efficacy and safety of viusid in a particular
48
49 population of elderly cirrhotic patients who had a previous history or current evidence of
50
51 clinical hepatic decompensation and genotype 1 infection, and therefore the poorest
52
53 chance of achieving SVR and elevated probabilities of adverse clinical outcome in their
54
55 next years of follow-up.
56
57
58
59
60

1
2
3
4 In the current study, we demonstrated that administration of a nutritional supplement to
5
6 HCV-related decompensated cirrhotic patients induced a significant improvement of
7
8 overall survival, as compared to placebo. Similarly, a significant reduction in the disease
9
10 progression, defined as the presence liver-related death, the development of
11
12 hepatocellular carcinoma or a first occurrence or relapse of at least one of the main portal
13
14 hypertension-related clinical complications, was observed in patients treated with viusid in
15
16 comparison to those patients treated with placebo. However, the effect of viusid on
17
18 survival and disease progression was irrelevant for patients with CP classes A, in contrast
19
20 to those patients with CP classes B or C. Interestingly; the cumulative incidence of HCC
21
22 was notably reduced in those patients assigned to experimental arm, compared to placebo
23
24 arm. However, a stratified analysis according to Child-Pugh classes was not performed,
25
26 due to a small proportion of patients with presence of HCC which could generate a bias in
27
28 the interpretation of the results.
29
30
31
32
33

34
35 In the present study, we found increased rates of mortality, disease progression and
36
37 cumulative incidence of HCC in the placebo group than previously reported rates in a
38
39 large, prospective and multicenter trial³⁷. The most likely explanation for the disparity
40
41 between these rates appears to be related to the difference in the study design. Our study
42
43 was designed to include a large proportion of patients who had a previous history or
44
45 current evidence of clinical hepatic decompensation (poor hepatic reserve), subjects who
46
47 were excluded from the HALT-C Trial³⁷. A recent controlled study has validated the
48
49 efficacy and safety of IFN-based therapy for HCV-related decompensated cirrhotic patients
50
51
52
53
54
55
56
57
58
59
60
14. One of the main advantages of the study was to include a group of untreated patients
(controls) with decompensated events who were enrolled to define survival and
progression disease during 30 months of follow-up. The results obtained in this study show

1
2
3
4 that this group of patients have a poor chance to survive (68%) and increased rates of
5
6 hepatic decompensation (88%) and HCC (10%). These results suggest that natural history
7
8 of HCV-related cirrhotic patients is more accelerated in patients with previous history or
9
10 current evidence of clinical hepatic decompensation.
11
12

13
14 Data from the HALT-C study show an increased annual risk of HCC in patients with a low
15
16 platelet count and the presence of esophageal varices. It could be another reasonable
17
18 theory to explain the increased risk of HCC in our study. In the current study, an elevated
19
20 percentage of patients (~50%) had evidence of esophageal varices and/or
21
22 thrombocytopenia ($<100 \times 10^3/\mu\text{L}$)³⁸.
23
24

25
26 Finally, an increased prevalence of diabetes was reported in our study (42% in placebo
27
28 group and 34% in viusid group), which has been associated with development of HCC and
29
30 accelerated disease progression³⁹.
31
32

33
34 In the current study, the rate of new occurrence or relapse of overall clinical outcome
35
36 secondary to portal hypertension was statistically reduced in the patients assigned to
37
38 viusid in comparison to those allocated to placebo. The cumulative incidence of ascites
39
40 was the only remarkable clinical condition reduced in the patients treated with viusid as
41
42 compared to placebo. In contrast, no differences were observed between the treatment
43
44 groups for hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal
45
46 syndrome, and upper gastrointestinal bleeding.
47
48

49
50 The benefit of viusid was also seen in the secondary end point of worsening of the
51
52 prognostic scores. A significant increase in the CP and MELD scores was observed in the
53
54 placebo-treated patients compared to the experimental group.
55
56
57
58
59
60

1
2
3
4 During the viusid therapy, the risk of bacterial infections decreased independently from
5
6 neutropenia, which could suggest an improvement in the qualitative neutrophil function,
7
8 but this effect should be additionally studied.
9

10
11 Viusid was well tolerated and only minor transient adverse events such as nausea and
12
13 diarrhea were reported.
14

15
16 The mechanisms responsible for the beneficial effects of viusid on the clinical outcomes
17
18 such as survival, development of HCC, and disease progression have not yet been fully
19
20 studied. However, there are several reasons to understand why its administration might
21
22 improve overall clinical end points.
23

24
25 A recent trial has suggested that viusid therapy combined with standard of care (SOC) in
26
27 patients with chronic hepatitis C may reduce inflammation and fibrosis, irrespective of
28
29 virological response³². Another recently published study has reported a dual role to
30
31 explain possible mechanisms of action of viusid on liver histology³³. The authors found
32
33 that MDA and 4-hydroxyalkenal levels were significantly reduced in patients treated with
34
35 viusid, indicating an important effect on lipid peroxidation products. Furthermore, viusid
36
37 provided immunomodulatory effects on cytokine secretion via increased production of anti-
38
39 inflammatory cytokines (IL-10) and decreased or stabilized production of pro-inflammatory
40
41 cytokines (IL-1 α and TNF- α). Current studies are focusing on the biological effects of
42
43 viusid on hepatic stellate cell apoptosis as a critical step to clarify the potential mechanism
44
45 of viusid in liver fibrogenesis. On the other hand, it would be important to evaluate whether
46
47 the viusid effects on the clinical outcomes are directly related to the significant reduction of
48
49 portal pressure in cirrhotic patients. Further studies should be addressed to answer this
50
51 concern.
52
53
54
55
56
57
58
59
60

1
2
3
4 Recently, the HALT-C study was designed to determine whether low-dose peginterferon
5 alpha 2a maintenance therapy over 3.5 years could reduce hepatic decompensation,
6 HCC, and mortality in patients with advanced fibrosis or cirrhosis who failed to achieve
7 SVR with SOC³⁷. Unfortunately, no overall reduction in any of these clinical end points
8 was achieved. Like the HALT-C study, 2 other studies (COPILOT and EPIC) failed to
9 demonstrate overall benefit on clinical outcomes in HCV-related cirrhotic patients⁴⁰⁻⁴¹. A
10 recent analysis of the HALT-C trial has demonstrated that benefits on clinical outcomes
11 could only be reached in patients with profound viral suppression obtained with full-dose
12 peginterferon and ribavirin¹⁹.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The main strength of this study was to demonstrate that viusid improves overall clinical
outcomes (survival, HCC, and disease progression) in cirrhotic patients who have failed to
achieve SVR with SOC, and these benefits appear to be not associated to viral
suppression rates³².

Our study was designed with a small sample size. Therefore, further multicentre and large-
scale studies are needed to corroborate the impact of viusid on the clinical outcomes in
patients with HCV-related decompensated cirrhosis.

In conclusion, the study supports the use of viusid in patients with HCV-related
decompensated cirrhosis who have failed to achieve SVR, with full-dose peginterferon and
ribavirin in an attempt to prevent disease progression and improve overall survival.

However, additional studies are required to confirm the long-term effect of viusid in
patients with poorer liver function (Child-Pugh B or C).

References

1. Thomas DL, Seeff LB. Natural history of hepatitis C. *Clin Liver Dis* 2005;**9**:383-98, vi.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005;**5**:558-67.
3. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. *Am J Gastroenterol* 2002;**97**:2886-95.
4. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology* 2006;**43**:1303-10.
5. Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. *Gut* 2004;**53**:744-9.
6. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). *J Hepatol* 1997;**27**:201-5.
7. Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. *Aliment Pharmacol Ther* 2010;**32**:344-55.
8. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. *Hepatology* 1999;**29**:1311-6.
9. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. *Liver Transpl* 2009;**15**:1063-71.

- 1
2
3
4 10. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination
5
6 therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver
7
8 cirrhosis. *Scand J Gastroenterol* 2008;**43**:1378-86.
- 9
10
11 11. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of
12
13 antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
14
15 *Liver Transpl* 2002;**8**:350-5.
- 16
17
18 12. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with
19
20 decompensated cirrhosis to prevent recurrence of hepatitis C after liver
21
22 transplantation. *J Hepatol* 2003;**39**:389-96.
- 23
24
25 13. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low
26
27 accelerating dosage regimen of antiviral therapy. *Hepatology* 2005;**42**:255-62.
- 28
29
30 14. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with
31
32 hepatitis C virus and decompensated cirrhosis: a controlled study. *J Hepatol*
33
34 2007;**46**:206-12.
- 35
36
37 15. Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-
38
39 interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. *Aliment*
40
41 *Pharmacol Ther* 2008;**27**:1081-5.
- 42
43
44 16. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of
45
46 hepatitis C: an update. *Hepatology* 2009;**49**:1335-74.
- 47
48
49 17. Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic
50
51 patients with chronic HCV infection. *Expert Opin Pharmacother* 2009;**10**:1929-38.
- 52
53
54 18. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-
55
56 alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective
57
58 study. *Hepatology* 2007;**45**:579-87.
- 59
60

- 1
2
3
4 19. Shiffman ML, Morishima C, Dienstag JL, et al. Effect of HCV RNA suppression during
5
6 peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
7
8 Gastroenterology 2009;**137**:1986-94.
9
- 10
11 20. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C
12
13 patients with sustained virological response to interferon monotherapy. Gut
14
15 2004;**53**:1504-8.
16
17
- 18 21. De Maria N, Colantoni A, Faggioli S, et al. Association between reactive oxygen species
19
20 and disease activity in chronic hepatitis C. Free Radic Biol Med 1996;**21**:291-5.
21
22
- 23 22. Boya P, de la Pena A, Belouqui O, et al. Antioxidant status and glutathione metabolism in
24
25 peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol
26
27 1999;**31**:808-14.
28
29
- 30 23. Gramenzi A, Andreone P, Loggi E, et al. Cytokine profile of peripheral blood mononuclear
31
32 cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat
33
34 2005;**12**:525-30.
35
36
- 37 24. Duarte TL, Lunec J. Review: When is an antioxidant not an antioxidant? A review of novel
38
39 actions and reactions of vitamin C. Free Radic Res 2005;**39**:671-86.
40
41
- 42 25. Lee CH, Park SW, Kim YS, et al. Protective mechanism of glycyrrhizin on acute liver
43
44 injury induced by carbon tetrachloride in mice. Biol Pharm Bull 2007;**30**:1898-904.
45
46
- 47 26. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects
48
49 Med 2005;**26**:391-404.
50
- 51 27. Abe M, Akbar F, Hasebe A, et al. Glycyrrhizin enhances interleukin-10 production by liver
52
53 dendritic cells in mice with hepatitis. J Gastroenterol 2003;**38**:962-7.
54
55
56
57
58
59
60

- 1
2
3
4
5 28. Yoshikawa M, Toyohara M, Ueda S, et al. Glycyrrhizin inhibits TNF-induced, but not Fas-
6 mediated, apoptosis in the human hepatoblastoma line HepG2. *Biol Pharm Bull*
7
8 1999;**22**:951-5.
9
10
11 29. Kimura M, Inoue H, Hirabayashi K, et al. Glycyrrhizin and some analogues induce growth
12 of primary cultured adult rat hepatocytes via epidermal growth factor receptors. *Eur J*
13
14 *Pharmacol* 2001;**431**:151-61.
15
16
17 30. Shimoyama Y, Sakamoto R, Akaboshi T, et al. Characterization of secretory type IIA
18 phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-
19 induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro. *Biol*
20
21 *Pharm Bull* 2001;**24**:1004-8.
22
23
24 31. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, et al. Clinical trial: a nutritional
25 supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic
26 fatty liver disease. *Aliment Pharmacol Ther* 2009;**30**:999-1009.
27
28
29 32. Vilar Gomez E, Gra Oramas B, Soler E, et al. Viusid, a nutritional supplement, in
30 combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
31
32 *Liver Int* 2007;**27**:247-59.
33
34
35 33. Gomez EV, Perez YM, Sanchez HV, et al. Antioxidant and immunomodulatory effects of
36 Viusid in patients with chronic hepatitis C. *World J Gastroenterol* 2010;**16**:2638-47.
37
38
39 34. Bruix J, Sherman M. Management of hepatocellular carcinoma. *Hepatology*
40
41 2005;**42**:1208-36.
42
43
44 35. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma.
45 Conclusions of the Barcelona-2000 EASL conference. European Association for the
46
47 Study of the Liver. *J Hepatol* 2001;**35**:421-30.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 36. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular
5
6 carcinoma. *Gastroenterology* 2005;**128**:1752-64.
7
8
9 37. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic
10
11 hepatitis C with low-dose peginterferon. *N Engl J Med* 2008;**359**:2429-41.
12
13
14 38. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and
15
16 associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology*
17
18 2009;**136**:138-48.
19
20
21 39. Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among
22
23 patients with hepatitis C cirrhosis and diabetes mellitus. *Hepatology* 2008;**47**:1856-62.
24
25
26 40. Afdhal NH, Levine R, Brown R, et al. Colchicine versus peginterferon alfa 2b long term
27
28 therapy: results of the 4 year copilot trial. *J Hepatol* 2008;**48**(Suppl 2):S4.
29
30
31 41. Bruix J, Poynard T, Colombo M, et al. Pegintron maintenance therapy in cirrhotic
32
33 (Metavir F4) HCV patients, who failed to respond to interferon/ribavirin therapy: final results
34
35 of the EPIC³ cirrhosis maintenance trial. *J Hepatol* 2009;**50**(Suppl 1):S22.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Ingredients of viusid

Malic acid	0.666 g	Ascorbic acid	0.020 g
Glycyrrhizic acid	0.033 g	Folic acid	66 mcg
Glucosamine	0.666 g	Cyanocobalamine	0.3 mcg
Arginine	0.666 g	Zinc sulfata	0.005 g
Glycine	0.333 g	Pyridoxal	0.6 mg
Calcium pantothenate	0.002 g		

Table 2. Baseline characteristics.

Variable	Viusid (n=50)	Placebo (n=50)	P value*
Age (y)	58.5±8.9	56.6±8.4	0.29
Sex, n (%)			
Male	22 (44%)	18 (36%)	0.41
Female	28 (56%)	32 (64%)	
BMI (kg/m ²)	25.4±4.6	26.7±4.5	0.16
BMI > 25 (kg/m ²), n (%)	28 (56%)	31 (62%)	0.54
HCV RNA >600,000 IU/ml	42 (84%)	38 (76%)	0.45
Genotype 1, n (%)	50 (100%)	50 (100%)	1.0
Clinical scores			
Child-Pugh Class A	32 (64%)	29 (58%)	0.56
Child-Pugh Class B	15 (30%)	15 (30%)	
Child-Pugh Class C	3 (6%)	6 (12%)	
MELD	12.5±3.7	13.3±4.7	0.46
History of diabetes or fasting glucose ≥ 7 (mmol/L), n (%)	17 (34%)	21 (42%)	0.41
Previous history of clinical decompensation, n (%)†			
Ascites	22 (44%)	14 (32%)	0.10
Upper gastrointestinal bleeding	9 (18%)	5 (10%)	0.25
Spontaneous bacterial peritonitis	2 (4%)	2 (4%)	1.00
Hepatic encephalopathy	4 (8%)	3 (6%)	0.69
Evidence of esophageal varices	23 (46%)	18 (36%)	0.31

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Current propranolol use, n (%)	13 (26%)	10 (20%)	0.65
Average doses	70±17.7	80±37.7	0.37
Current spironolactone use, n (%)	21 (42%)	12 (24%)	0.09
Average doses	84.5±39.1	111±40	0.14
Current furosemide use, n (%)	4 (8%)	5 (10%)	1.00
Average doses	40±10	64±22	0.19
ALT (U/L)	92.2±76.6	82.7±49.5	0.86
AST (U/L)	105±80.2	94.1±56.6	0.72
Fasting plasma glucose (mmol/L)	4.9±1.2	5.1±1.3	0.70
Alkaline phosphatase (mmol/L)	290.4±108	281±78.8	0.96
Creatinine (mmol/L)	1±0.3	1±0.3	0.88
Hemoglobin (g/L)	125.8±13.8	129.5±17.6	0.32
Cholesterol (mmol/L)	3.85±0.9	3.85±1	0.50
Total bilirubin (mmol/L)	24.3±17.6	23.9±17.7	0.98
Albumin (g/L)	38.9±4.3	38.9±4.3	0.52
Partial thromboplastin time (s)	38.4±9.7	39.3±12.3	0.73
Prothrombin time (s)	4.7±2.5	5.5±3.7	0.38
INR	1.49±0.3	1.58±0.4	0.38
White blood cells (x 10 ³ /μL)	6.1±1.9	5.9±1.7	0.70
Platelets (x 10 ³ /μL)	133.7±57.9	130.6±65.7	0.48
Platelets < 100 x 10 ³ /μL	20 (40%)	24 (48%)	0.42
α-fetoprotein (ng/ml)	11±16.9	10±12.7	0.25

* P values are for the comparison between viusid and placebo.

† Previous history of clinical decompensation within one year before enrollment.

1
2
3
4 Plus-minus values are means \pm standard deviations.

5
6 For all laboratory measures and for continuous demographics: P value Mann-Whitney *U*-test.

7
8 Proportions: percentage, P value chi-square.

9
10
11 MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate
12 aminotransferase.

13
14
15 The Child-Pugh and MELD scores are measures of the severity of liver disease.

16
17 Prothrombin time (s): value is expressed in seconds upper the control.

18
19 Partial thromboplastin time (s): value in seconds.

20
21 To convert mmol/L of bilirubin to mg/dL, multiply by 0.0585.

22
23 To convert mmol/L of creatinine to mg/dL, multiply by 0.01131.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. Summary of outcome measures.

Variable	Viusid (N=50) No. of patients (%)	Placebo (N=50) No. of patients (%)	Hazard Ratio* (95% CI)	P value
Primary outcomes – no. (%)				
Overall survival	45 (90%)	37 (74%)	0.27 (0.08-0.92)	0.036
Secondary outcomes – no. (%)				
Time to disease progression	14 (28%)	24 (48%)	0.47 (0.22-0.89)	0.044
Time to diagnosis of HCC†	1 (2%)	6 (12%)	0.15 (0.019-0.90)	0.046
Worsening of CP score in at least 2 points	7 (14%)	19 (38%)	0.34 (0.14-0.81)	0.015
Worsening of MELD score in at least 4 points	6 (12%)	15 (30%)	0.39 (0.15-0.92)	0.042
Ascites	7 (14%)	16 (32%)	0.32 (0.11-0.90)	0.031
Hepatic encephalopathy	1 (2%)	5 (10%)	0.20 (0.10-1.7)	0.10
Spontaneous bacterial peritonitis	1 (2%)	5 (10%)	0.20 (0.13-1.7)	0.09

1
2
3
4 Upper gastrointestinal bleeding 8 (16%) 10 (20%) 0.78 (0.31-1.99) 0.67
5
6

7 *Hazard ratios were computed using Cox proportional hazard model adjusted for sex and age, baseline CP and MELD scores, previous
8 history of clinical decompensation, and current use of diuretics and propranolol. CI denotes confidence interval for HR.
9

10 †All cases of HCC were diagnosed during the second year of treatment.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 4. Incidence of adverse events*.

Variable	Viusid (n=50)	Placebo (n=50)	P value†
	No (%)	No (%)	
Asthenia	12 (24%)	20 (40%)	0.08
Fatigue or malaise	5 (10%)	13 (26%)	0.04
Muscle pain	8 (16%)	16 (32%)	0.06
Anorexia	5 (10%)	9 (18%)	0.24
Cramps	11 (22%)	22 (44%)	0.02
Discomfort on the RUC‡	7 (14%)	13 (26%)	0.13
Gingival bleeding	5 (10%)	10 (20%)	0.16
Epistaxis	5 (10%)	10 (20%)	0.16
Nausea	5 (10%)	1 (2%)	0.12
Diarrhea	5 (5%)	1 (2%)	0.12
Sepsis	7 (14%)	20 (40%)	<0.01
Hospitalization	9 (18%)	15 (30%)	0.24

* The adverse events listed are those recorded in at least 5% of the patients in either study group.

† P values were calculated on the basis of the two-sided chi-square.

‡ RUC: right upper quadrant.

FIGURE LEGENDS:**Fig. 1. Flow of patients through the study.**

*Four patients with HCC were not discontinued because diagnosis was made at the end of the treatment.

Fig. 2. Kaplan-Meier curves for survival (Panel A) and time to disease progression (Panel B)* according to Child-Pugh classes (A versus B or C).

*Time to disease progression was defined as the incidence of liver-related death, the development of hepatocellular carcinoma, or the first occurrence or relapse (only for those patients with a previous history of hepatic decompensation) of at least one of the following clinical conditions: ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, or upper gastrointestinal bleeding secondary to portal hypertension. The Child-Pugh score is a measure of the severity of liver disease.

Parentheses show number of events.

CP, Child-Pugh class.

Fig. 3. Kaplan-Meier estimates of the time to worsening of the Child-Pugh (Panel A) and MELD (Panel B) scores during the treatment.

Parentheses show number of events.

The MELD and Child-Pugh score are measures of the severity of liver disease.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. Patient flow
215x279mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



84x59mm (300 x 300 DPI)

view only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



69x50mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




50x36mm (300 x 300 DPI)

View only

CONSORT Statement 2001 - Checklist 
 Items to include when reporting a randomized trial

<i>PAPER SECTION And topic</i>	Item	Descriptor	Reported on Page #
<i>TITLE & ABSTRACT</i>	1	<u>How participants were allocated to interventions</u> (e.g., "random allocation", "randomized", or "randomly assigned").	1,3
<i>INTRODUCTION Background</i>	2	<u>Scientific background and explanation of rationale.</u>	6-8
<i>METHODS Participants</i>	3	<u>Eligibility criteria for participants</u> and the <u>settings and locations where the data were collected.</u>	9
Interventions	4	<u>Precise details of the interventions intended for each group and how and when they were actually administered.</u>	10
Objectives	5	<u>Specific objectives and hypotheses.</u>	8
Outcomes	6	<u>Clearly defined primary and secondary outcome measures</u> and, when applicable, any <u>methods used to enhance the quality of measurements</u> (e.g., multiple observations, training of assessors).	11-12
Sample size	7	<u>How sample size was determined</u> and, when applicable, <u>explanation of any interim analyses and stopping rules.</u>	13
Randomization -- Sequence generation	8	<u>Method used to generate the random allocation sequence, including details of any restrictions</u> (e.g., blocking, stratification)	10
Randomization -- Allocation concealment	9	<u>Method used to implement the random allocation sequence</u> (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.	10
Randomization -- Implementation	10	<u>Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups.</u>	10
Blinding (masking)	11	<u>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment.</u> If done, <u>how the success of blinding was evaluated.</u>	10
Statistical methods	12	<u>Statistical methods used to compare groups for primary outcome(s); Methods for additional analyses</u> , such as subgroup analyses and adjusted analyses.	13
<i>RESULTS Participant flow</i>	13	<u>Flow of participants through each stage</u> (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. <u>Describe protocol deviations from study as planned, together with reasons.</u>	14 Figure 1
Recruitment	14	<u>Dates defining the periods of recruitment and follow-up.</u>	14
Baseline data	15	<u>Baseline demographic and clinical characteristics of each group.</u>	14
Numbers analyzed	16	<u>Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat".</u> State the results in absolute numbers when feasible (e.g., 10/20, not 50%).	14
Outcomes and estimation	17	<u>For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision</u> (e.g., 95% confidence interval).	15-16
Ancillary analyses	18	<u>Address multiplicity by reporting any other analyses performed</u> , including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.	15-16
Adverse events	19	<u>All important adverse events or side effects in each intervention group.</u>	16
<i>DISCUSSION Interpretation</i>	20	<u>Interpretation of the results</u> , taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.	16-21
Generalizability	21	<u>Generalizability (external validity) of the trial findings.</u>	16-21
Overall evidence	22	<u>General interpretation of the results in the context of current evidence.</u>	16-21

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



50x36mm (300 x 300 DPI)

View only